

Figure 5. Simple photophysical scheme describing a possible pathway for sensitization of Yb luminescence in PAN-DOTA(Yb).

absorption wavelength was shifted to around 560 nm by chelation with the zinc ion,^[14] these data indicate that the DOTA chelation of Yb ion does not have a major effect on the energy level of the PAN moiety.

A sharp and strong emission peak at 975 nm detected in the PAN-DOTA(Yb) emission spectrum ($\lambda_{\text{ex}} = 530$ nm) can be assigned to a typical Yb ${}^2F_{5/2}$ to ${}^2F_{7/2}$ transition. The emission feature disappeared with the lack of PAN moiety or Yb ion. These results suggest that the 975 nm luminescence shown in PAN-DOTA(Yb) is derived from energy transfer from an excited PAN moiety to the Yb fluorescent center.

PAN-DOTA(Yb) emits NIR fluorescence through its excitation by visible light with a very large Stoke's shift, as expected. These features are similar to our previous compound [4AMF-DOTA(Nd)], which has a fluorescence at 880 nm from excitation by 488 nm light.^[15] In addition, an undesirable fluorescence around 525 nm from the antenna moiety present in 4AMF-DOTA(Nd) was eliminated by using a non-fluorescent antenna moiety in PAN-DOTA(Yb). The peak fluorescent counts originating from lanthanide were measured to be 2188 [PAN-DOTA(Yb), $\lambda_{\text{em}} = 975$ nm] and 2220 [4AMF-DOTA(Nd), $\lambda_{\text{em}} = 880$ nm], and the noise fluorescent counts not originating from lanthanide ($\lambda_{\text{em}} = 800$ nm) were 1038 [PAN-DOTA(Yb)] and 4786 [4AMF-DOTA(Nd)]. Therefore, the signal-to-noise ratios were 2.10 [PAN-DOTA(Yb)] and 0.46 [4AMF-DOTA(Nd)]. These data indicate that PAN-DOTA(Yb) could be superior to 4AMF-DOTA(Nd) for *in vivo* fluorescence molecular imaging with an expected increase in signal-to-noise ratio.

Although the mechanism of energy transfer from the PAN moiety to Yb ion is still unclear, the triplet excitation state of the antenna moiety might participate in this process.^[16] A simple model of this process is depicted in Fig. 5.

PAN-DOTA(Yb) had a stable fluorescent feature over a wide pH range (pH 3–11). In contrast, we reported previously that the fluorescence from 4AMF-DOTA(Nd) disappeared at pH < 5.0 due to its pH-sensitive functional groups. Thus, PAN-DOTA(Yb), with a more favorable pH fluorescence profile, is considered to be superior to 4AMF-DOTA(Nd) as a probe, especially for *in vivo* applications. In addition, the high stability from the decomposition in solution indicate that PAN-DOTA(Yb) could be widely employed as a fluorescence imaging probe in pH-fluctuating environments.

Even though the excitation peak of PAN-DOTA(Yb) was slightly changed by the solvent, the emission peak was not susceptible to environmental changes, not only the pH but also the solvent. The lack of solvent effect on emission wavelength is due to a characteristic of lanthanide ions in which the 5s and 5d orbitals are located outside the 4f orbital responsible for fluorescence, resulting in protection from environmental influences. These data further support the notion of the observed fluorescence around 975 nm being derived from the Yb ion. PAN-DOTA(Yb) displayed a stronger emission intensity in organic solvents than in buffer, probably because H₂O can act as a quencher for excited PAN-DOTA(Yb) in some processes.

These quantum yield values are slightly diminished as compared with other Yb complexes reported previously.^[13,17,18] This effect may partially reflect differences in structure, in particular, the distance between the chromophore (PAN moiety) and the fluorophore [DOTA(Yb) moiety]. In many reports, the Yb ion was directly coordinated by the chromophore, but in the case of PAN-DOTA(Yb), the PAN moiety does not coordinate to the Yb, as indicated by small change in the UV-vis spectrum after Yb complexation. Thus, the energy transfer ratio from the PAN moiety to DOTA(Yb) would be lower than for directly coordinated complexes. While most of the previously reported complexes tend to be influenced by their surroundings, PAN-DOTA(Yb), because of the structural independence of fluorescent center and antenna moiety, has a stable fluorescence under many conditions.

As expected, PAN-DOTA(Yb) shows higher quantum yields in organic solvents than in buffer [Fig. 4(A)]. This is a common feature of many lanthanide (e.g. Nd³⁺, Yb³⁺, Er³⁺) complexes because the luminescence from lanthanide ions is susceptible to vibratory quenching by O–H oscillators.

Conclusion

The results obtained in this study indicate that PAN-DOTA(Yb) has the potential for *in vivo* fluorescence imaging with several favorable properties, such as near-infrared luminescence, visible light excitation, and a large Stoke's shift. In addition, a negligible fluorescence from the PAN moiety and pH-stability are other potential advantages of PAN-DOTA(Yb).

References

- [1] Fu G, Yang HY, Wang C, Zhang F, You ZD, Wang GY, He C, Chen YZ, Xu ZZ. Detection of constitutive heterodimerization of the integrin Mac-1 subunits by fluorescence resonance energy transfer in living cells. *Biochem Biophys Res Commun* 2006;346:986–91.
- [2] Wandelt B, Cywinski P, Darling GD, Stranix BR. Single cell measurement of micro-viscosity by ratio imaging of fluorescence of styrylpyridinium probe. *Biosens Bioelectron* 2005;20:1728–36.
- [3] Mizukami S, Kikuchi K, Higuchi T, Urano Y, Mashima T, Tsuruo T, Nagano T. Imaging of caspase-3 activation in HeLa cells stimulated with etoposide using a novel fluorescent probe. *FEBS Lett* 1999;453:356–60.
- [4] König K. Multiphoton microscopy in life sciences. *J Microsc* 2000;200:83–104.
- [5] Colette S, Amekraz B, Madic C, Berthon L, Cote G, Moulin C. Europium(III) interaction with a polyaza-aromatic extractant studied by time-resolved laser-induced luminescence: a thermodynamic approach. *Inorg Chem* 2004;43:6745–51.
- [6] Quici S, Marzanni G, Forni A, Accorsi G, Barigelletti F. New lanthanide complexes for sensitized visible and near-IR light emission: synthesis, ¹HnmR, and X-ray structural investigation and photophysical properties. *Inorg Chem* 2004;43:1294–301.
- [7] Gunnlaugsson T, MacDonall DA, Parker D. Lanthanide macro-cyclic quinuoyl conjugates as luminescent molecular-level devices. *J Am Chem Soc* 2001;123:12866–76.

- [8] Werts MHV, Hofstraat JW, Geurts FAJ, Verhoeven JW. Fluorescein and eosin as sensitizing chromophores in near-infrared luminescent ytterbium(III), neodymium(III) and erbium(III) chelates. *Chem Phys Lett* 1997;276:196–201.
- [9] Faulkner S, Carrie MC, Pope SJ, Squire J, Beeby A, Sammes PG. Pyrene-sensitised near-IR luminescence from ytterbium and neodymium complexes. *Dalton Trans* 2004:1405–9.
- [10] Beer PD, Szemes F, Passaniti P, Maestri M. Luminescent ruthenium(II) bipyridine-calix[4]arene complexes as receptors for lanthanide cations. *Inorg Chem* 2004;43:3965–75.
- [11] Hasegawa Y, Ohkubo T, Sogabe K, Kawamura Y, Wada Y, Nakashima N, Yanagida S. Luminescence of novel neodymium sulfonylamine complexes in organic media. *Angew Chem Int Ed Engl* 2000;39:357–60.
- [12] Wu SL, Horrocks WD. Direct determination of stability constants of lanthanide ion chelates by laser-excited europium(III) luminescence spectroscopy: application to cyclic and acyclic aminocarboxylate complexes. *J Chem Soc Dalton Trans* 1997:1497–502.
- [13] Zhang J, Badger PD, Geib SJ, Petoud S. Sensitization of near-infrared-emitting lanthanide cations in solution by tropolonate ligands. *Angew Chem Int Ed Engl* 2005;44:2508–12.
- [14] Malik AK, Sharma V, Sharma VK, Rao AL. Column preconcentration and spectrophotometric determination of ziram and zineb in commercial samples and foodstuffs using (1,2'-pyridylazo)-2-naphthol (PAN)-naphthalene as adsorbate. *J Agric Food Chem* 2004;52:7763–7.
- [15] Aita K, Temma T, Kuge Y, Saji H. Development of a novel neodymium compound for *in vivo* fluorescence imaging. *Luminescence* 2007;22:455–61.
- [16] Crosby GA, Alire RM, Whan RE. Intramolecular energy transfer in rare earth chelates—role of triplet state. *J Chem Phys* 1961;34:743–8.
- [17] Foley TJ, Harrison BS, Knefely AS, Abboud KA, Reynolds JR, Schanze KS, Boncella JM. Facile preparation and photophysics of near-infrared luminescent lanthanide(III) monoporphyrinate complexes. *Inorg Chem* 2003;42:5023–32.
- [18] Zhang J, Petoud S. Azulene-moiety-based ligand for the efficient sensitization of four near-infrared luminescent lanthanide cations: Nd³⁺, Er³⁺, Tm³⁺, and Yb³⁺. *Chemistry* 2008;14:1264–72.



不安定性動脈硬化プラークイメージングのための分子プローブ開発研究

京都大学大学院薬学研究科病態機能分析学分野 天満 敬、佐治英郎

1. はじめに

近年、動脈内のプラーク破綻とそれに伴う血栓形成が心筋梗塞や脳梗塞の発症に深く関与していることが明らかとなり、動脈内のプラークの不安定性を精度よく評価できる診断法の開発が切望されている。これまでに、超音波診断法、MRI、X線CT等を用いた検討が行われているが、未だ形態的検討が主で、質的診断に有効な方法は開発されていない¹⁾。一方、PET、SPECTを用いる核医学分子イメージング法は、生体内機能分子をインビボで非侵襲的かつ定量的に画像化できるため、動脈硬化プラークの不安定化に関与する機能分子を標的とする分子プローブを用いることで動脈硬化の質的診断への応用が期待されている。本稿では、我々の研究室において実施された不安定性動脈硬化プラークイメージングに関する研究の概略を紹介したい。

1. 不安定性動脈硬化プラークとは

不安定性動脈硬化プラークの特徴として、①脂質に富む柔らかな粥腫があること②線維性被膜が脆弱化していること③マクロファージなどの炎症性細胞が浸潤していること、が挙げられる。一方、安定プラークでは線維性組織が発達し内膜の肥厚は認められるものの、マクロファージの浸潤はほとんど無い^{7,10)} (図1)。

2. ¹⁸F-FDG

不安定性動脈硬化プラークの特徴のひとつにマクロファージの存在がある。そこで、マクロファージではエネルギー代謝が活発であり、そのエネルギー源として糖(グルコース)を用いていることに着目し、糖代謝イメージング剤である¹⁸F-FDGを用いた不安定プラークイメージングが試みられてきている。当研究室においては、不安定性動脈硬化プラークへの¹⁸F-FDGの集積を基礎的に検討するために、動脈硬化モデル動物であるWatanabe heritable hyperlipidemic (WHHL)ウサギに¹⁸F-FDGを投与し、マクロファージ浸潤度と放射能集積量の関連、PETを用いたイメージング検討を行った²⁾。その結果、¹⁸F-FDGは対照群であるNZWウサギの血管に比較してWHHLウサギの血管へ有意に高く集積し、また、その集積量はマクロファージ数と高い相関を示すことを見出した(図2A)。一方、内膜の肥厚度と放射能集積量との間には相関は認められなかった(図2B)。このことから、¹⁸F-FDGの集積には安定プラークでも認められる内膜の肥厚度ではなく、不安定プラーク




図1 不安定プラーク(左)、安定プラーク(右)の典型例

クで特異的に増加しているマクロファージが関与していることを示した。さらに、PET撮像により、動脈硬化病変を示す大動脈血管を¹⁸F-FDG投与と3~4時間後に明確に描出できた(図2C, D)。これらの結果は、¹⁸F-FDGが不安定プラークを描出することの科学的基盤を与えた。さらに、不安定プラークの薬物治療効果の評価は、治療方針決定や新しい治療薬開発に有効であることから、




図2 2, 3) (A) ¹⁸F-FDG集積とマクロファージ数との関連 (B) ¹⁸F-FDG集積と内膜肥厚度との関連 (C) PET/CT画像-WHHLウサギ (D) PET/CT画像-NZWウサギ 矢(オレンジ)、矢じり(オレンジ)、矢じり(白)はそれぞれ動脈、腎臓、肝臓を示す (E) 薬剤治療による¹⁸F-FDG集積変化




図3⁴⁻⁶⁾ (A) LOX-1発現量とプラーク不安定性との関連
 (B) LOX-1発現量と^{99m}Tc標識抗LOX-1抗体集積との関連
 (C) プラナー画像-WHHLウサギ (D) プラナー画像-JWウサギ
 白矢印、L、S、Kはそれぞれ動脈、肝臓、脾臓、腎臓を示す
 (E) ^{99m}Tc標識抗LOX-1抗体と^{99m}Tc標識annexin A5の病変集積量比較 (*P<0.0001, #P<0.005, †P<0.01) N、A、F、Cはそれぞれ新生内膜病変、アテローム性病変(不安定プラーク)、フィブリアテローム性病変、コラーゲンリッチ病変である

¹⁸F-FDG-PET法の薬物治療評価への応用可能性を検討した³⁾。すなわち、myocardial infarction-prone WHHL (WHHLMI)ウサギに動脈硬化治療薬であるプロブコールを含む餌を与え、¹⁸F-FDGの放射能集積変化を経時的に調べた。その結果、血管への放射能集積が薬剤投与3ヵ月後から減少し、6ヶ月後には血管が描出されなくなった(図2E)。これにより、¹⁸F-FDG-PET法が不安定プラークにおける薬物治療評価に有効であることを示した。

3. スカベンジャー受容体イメージング

糖代謝亢進を集積原理とする¹⁸F-FDGは、元来エネルギー活動の活発な心筋に高く集積し、動脈硬化病変の好発部位である冠動脈への適用は困難という問題点がある。また、¹⁸F-FDGは初期の動脈硬化病変にも集積することから、新たに、疾患の進行度を評価可能な不安定プラークの質的診断用イメージングプローブの開発が求められている。

そこで我々は、動脈硬化プラークの不安定化に関与する、血管内皮細胞への炎症細胞の接着促進、マクロファージの泡沫化促進、コラーゲン線維の分解などに重要な役割を果たす可能性が細胞を用いた実験結果から示されている、酸化LDL受容体ファミリーの一つであるLectin-like oxidized LDL receptor-1 (LOX-1)を不安定プラークイメージングの標的分子として着目した。組織学的検討により、LOX-1の発現はプラークの不安定性の指標と高い相関を示し、LOX-1が標的分子として有効であることを見出した(図3A)^{4,11)}。そこで次に、LOX-1イメージング剤として^{99m}Tc標識抗LOX-1抗体の開発を計画し、二官能性キレートという分子設計概念に基づいて

^{99m}Tc標識抗LOX-1抗体を合成し、その体内分布挙動をWHHLMIウサギを用いて検討した結果⁵⁾、血管への放射能集積はLOX-1の発現量、および、プラークの不安定性の指標と高く相関することを見出した(図3B)。また、開発した^{99m}Tc標識抗LOX-1抗体を用いて投与24時間後に核医学イメージングを行った結果、コントロールウサギではほとんど大動脈が描出されないのに対して、WHHLMIウサギでは明瞭に大動脈が描出されることを認めた(図3C, D)。さらに、^{99m}Tc標識抗LOX-1抗体は、現在動脈硬化プラークの核医学診断用放射性薬剤として有力視されている^{99m}Tc標識annexin A5と比較して、動脈硬化病変への放射能集積、および、比較的安定な病変に対する放射能集積比の両者において高い値を示した(図3E)⁶⁾。以上の結果より、不安定プラークイメージング剤として^{99m}Tc標識抗LOX-1抗体の開発に成功した。さらに、この成果を基盤に不安定プラークのPETイメージング剤として⁶⁴Cu、⁶⁸Ga標識抗LOX-1抗体の開発を検討中である。

4. おわりに

癌(悪性新生物)に次ぐ日本人の死因は心疾患・脳血管疾患であり、この二つを合わせると癌に匹敵する数となる。したがって、これらの引き金となる不安定プラークの質的診断法の開発が切望され、様々な分子プローブが開発されつつある。本稿では浸潤マクロファージのエネルギー活動を集積機序とする¹⁸F-FDG、プラークの不安定性と関連するLOX-1を標的とする^{99m}Tc標識抗LOX-1抗体に関する研究を紹介した。今後さらに、¹⁸F-FDG、^{99m}Tc標識抗LOX-1抗体に加えて、破綻を起こす危険性の高い不安定プラークを特異的に検出することのできる分子プローブが開発されれば、¹⁸F-FDG、^{99m}Tc標識抗LOX-1抗体と組み合わせることで、動脈硬化疾患の病態進行の把握が可能となり、効果的・効率的なテーラーメイド医療の推進が期待される。

参考文献

- 1) Choudhury R. P., Fuster V. and Fayad Z. A., *Nat Rev Drug Discov*, **3**, 913-25, (2004)
- 2) Ogawa M., Ishino S., Mukai T., Asano D., Teramoto N., Watabe H., Kudomi N., Shiomi M., Magata Y., Iida H. and Saji H., *J Nucl Med*, **45**, 1245-50, (2004)
- 3) Ogawa M., Magata Y., Kato T., Hatano K., Ishino S., Mukai T., Shiomi M., Ito K. and Saji H., *J Nucl Med*, **47**, 1845-50, (2006)
- 4) Ishino S., Mukai T., Kume N., Asano D., Ogawa M., Kuge Y., Minami M., Kita T., Shiomi M. and Saji H., *Atherosclerosis*, **195**, 48-56, (2007)
- 5) Ishino S., Mukai T., Kuge Y., Kume N., Ogawa M., Takai N., Kamihashi J., Shiomi M., Minami M., Kita T. and Saji H., *J Nucl Med*, **49**, 1677-85, (2008)
- 6) Ishino S., Kuge Y., Takai N., Tamaki N., Strauss H. W., Blankenberg F. G., Shiomi M. and Saji H., *Eur J Nucl Med Mol Imaging*, **34**, 889-99, (2007)
- 7) Libby P., Geng Y. J., Aikawa M., Schoenbeck U., Mach F., Clinton S. K., Sukhova G. K. and Lee R. T., *Curr Opin Lipidol*, **7**, 330-5, (1996)
- 8) Zhou J., Chew M., Ravn H. B. and Falk E., *Scand J Clin Lab Invest Suppl*, **230**, 3-11, (1999)
- 9) Libby P., *Am J Cardiol*, **86**, 3J-8J; discussion 8J-9J, (2000)
- 10) Virmani R., Burke A. P., Farb A. and Kolodgie F. D., *Prog Cardiovasc Dis*, **44**, 349-56, (2002)
- 11) Kuge Y., Kume N., Ishino S., Takai N., Ogawa Y., Mukai T., Minami M., Shiomi M. and Saji H., *Biol Pharm Bull*, **31**, 1475-82, (2008)

Development of a Radiolabeled Probe for Detecting Membrane Type-1 Matrix Metalloproteinase on Malignant Tumors

Takashi TEMMA,^a Kohei SANO,^a Yuji KUGE,^{*,a,b} Junko KAMIHASHI,^a Nozomi TAKAI,^a Yuki OGAWA,^a and Hideo SAJI^a

^aDepartment of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University; 46–29 Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto 606–8501, Japan; and ^bDepartment of Tracer Kinetics & Bioanalysis, Graduate School of Medicine, Hokkaido University; Kita 15 Nishi 7, Kita-ku, Sapporo 060–8638, Japan.

Received February 3, 2009; accepted May 7, 2009; published online May 8, 2009

Membrane type-1 matrix metalloproteinase (MT1-MMP) expressed on the tumor cell surface activates pro-MMP-2 and pro-MMP-13 to exacerbate the malignancy, suggesting its suitability as a target molecule for diagnosis by *in vivo* molecular imaging. Thus, we prepared radiolabeled anti-MT1-MMP monoclonal antibody (mAb) as a novel radiolabeled probe for detecting MT1-MMP *in vivo* and evaluated its usefulness in breast tumor-bearing rodents. ^{99m}Tc-anti-MT1-MMP mAb was prepared using HYNIC as a bifunctional chelating agent and immunoreactivity was evaluated by flow cytometry. MT1-MMP expression in breast carcinoma cells (rat: Walker-256 and MRMT-1, mouse: FM3A) was measured by Western blotting. *In vivo* biodistribution was examined for 48 h using tumor-implanted rodents followed by estimation of radiation absorbed by a standard quantitation platform Organ Level Internal Dose Assessment (OLINDA). ^{99m}Tc-anti-MT1-MMP mAb was obtained with 84% immunoreactivity to MT1-MMP and more than 92% radiochemical purity. MT1-MMP was highly expressed in all malignant cells. Tumor radioactivity increased with time after administration and reached 3 to 5 times higher values at 24 h post-injection than those at 1 h. Other organs, including the stomach, showed decreasing values over time. Tumor to blood ratios increased with time and reached more than 1.3 at 48 h. The effective dose was <5.0 μSv/MBq. The results suggest that ^{99m}Tc-anti-MT1-MMP mAb is a promising probe for future diagnosis of breast tumors by *in vivo* nuclear medical imaging.

Key words membrane type-1 matrix metalloproteinase; breast tumor; non-invasive imaging; single photon emission computed tomography

Effective methods for detecting malignant tumors in the early phase before any obvious progression has occurred permits optimal conditions for successful therapy.^{1,2)} Nuclear medical techniques such as single photon emission computed tomography (SPECT) and positron emission tomography (PET) are non-invasive and have the potential to provide sensitive diagnoses. Both techniques detect radiation emitted from a radiolabeled probe targeted to a biological molecule relevant to tumor malignancy.

Matrix metalloproteinases (MMPs) play important roles in tumor growth, invasion and metastasis by degrading extracellular matrix components.³⁾ MMPs are classified as secreted MMPs or membrane-associated MMPs (MT-MMPs) based on their structure.⁴⁾ Among MT-MMPs, MT1-MMP activates pro-MMP-2 and pro-MMP-13 on the cell surface especially at lamellipodia, the migration front of cells.⁵⁾ Therefore, MT1-MMP has a close relationship with tumor malignancy.^{6,7)} As a target molecule of a radiolabeled probe, it is important to be localized at the site of malignancy in order to obtain clear images that can be readily compared or fused to anatomical information. In cases where target molecules are secreted to the surrounding tissues or bodily fluids including blood, a fall of signal to noise ratio in images is inevitable. MT1-MMP is a good candidate target as expression of MT1-MMP remains localized in tumor tissues⁴⁾ and increases in the early phase of exacerbation.⁸⁾ Further, since the amino acid sequences of MT1-MMP protein are well preserved among species including mouse, rat, rabbit and human,⁹⁾ results obtained in experiments using rodents and MT1-MMP probes may provide important information for clinical applications. Thus, MT1-MMP is a potential target for imaging

and diagnosing malignant tumors at early phases. Among all types of tumors, breast cancer remains a predominant cause of death from cancer in women despite advances in the treatment, especially in cases where distant metastases occur.¹⁰⁾ This motivated us to select breast cancer as a target disease for investigation of the MT1-MMP probe.

To the best of our knowledge, there have been no reports on the development of an MT1-MMP imaging agent for *in vivo* nuclear medical imaging. Therefore, in this study, we prepared Tc-99m-labeled anti-MT1-MMP monoclonal antibody and evaluated its usefulness through biodistribution studies using three kinds of rodent models bearing breast tumor allografts.

MATERIALS AND METHODS

Preparation of ^{99m}Tc-Anti-MT1-MMP mAb All chemicals used in this study were commercial products of the highest purity. ^{99m}Tc-pertechnetate was eluted in saline solution on a daily basis from ⁹⁹Mo-^{99m}Tc generators (Ultra-Techne Kow[®], FUJIFILM RI Pharma Co., Ltd., Tokyo, Japan). Succinimidyl hydrazinopyridine-3-carboxylate (HYNIC-NHS) was synthesized following the procedure reported previously.¹¹⁾ Anti-MT1-MMP mAb (113-5B7, Daiichi Fine Chemical Co., Ltd., Toyama, Japan), a purified mouse monoclonal antibody to an oligopeptide (residues 319 to 333, numbered from the signal peptide) of human MT1-MMP, was used for experiments after further purification on a HiTrap rProtein A column (17-5080-01, GE Healthcare, U.K.). HYNIC-NHS (25 μl, 5 mg/ml) in dry *N,N*-dimethylformamide (DMF) was added to anti-MT1-MMP mAb solu-

* To whom correspondence should be addressed. e-mail: kuge@med.hokudai.ac.jp

tion in 0.15 M borate buffer (pH 8.5, 2 mg/400 μ l). After gentle stirring with protection from light for 2 h at room temperature, size-exclusion filtration with a diafiltration membrane (Amicon Ultra 4 (MWCO 30000), Millipore Co., Billerica, MA, U.S.A.) using 0.01 M citrate buffer (pH 5.2) was performed to obtain HYNIC-anti-MT1-MMP mAb. The protein concentration of the purified solution was determined by the bicinchoninate (BCA) method.¹²⁾

An equal volume of ^{99m}Tc-(tricine)₂ (530 \pm 18 MBq), prepared by the method of Larsen *et al.*,¹³⁾ was added to a solution of HYNIC-anti-MT1-MMP mAb (1 ml, 1 mg/ml) in 0.01 M citrate buffer (pH 5.2). After 3 h at room temperature, size-exclusion filtration with a PD-10 column using 0.05 M phosphate buffered saline (PBS) (pH 7.0) was performed to obtain the ^{99m}Tc-anti-MT1-MMP mAb. Radiochemical purity of ^{99m}Tc-anti-MT1-MMP mAb, evaluated by another size-exclusion filtration (PD-10 column), was more than 92%. Radiochemical yield was 29.9 \pm 7.5%. Mouse immunoglobulin G₃ (IgG₃), kappa mAb (ab18392, Abcam, Cambridge, U.K.) was radiolabeled in a similar way as a negative control for biodistribution studies.

Immunoreactivity of HYNIC-Anti-MT1-MMP mAb Antibodies (50 μ g/ml, 100 μ l; anti-MT1-MMP mAb, HYNIC-anti-MT1-MMP mAb or negative control IgG₃ (sc-3880, Santa Cruz Biotechnology, California, U.S.A.)) were added to mouse macrophage cells (RAW264.7, 2 \times 10⁶ cells) and incubated in 0.01 M PBS (pH 7.4, 100 μ l) for 30 min on ice. After washing with 0.01 M PBS, Alexa Fluor[®] 488 goat anti-mouse IgG antibody (A-11001, Molecular Probes, Eugene, OR, U.S.A.) (10 μ g/ml, 100 μ l) was added for 30 min on ice. Fluorescence levels were measured using a flow cytometer (Becton Dickinson Inc., Franklin Lakes, NJ, U.S.A.). Data were analyzed using BD CellQuest Pro (BD Biosciences, San Jose, CA, U.S.A.) and a figure was calculated by the following equation: median fluorescence intensity of anti-MT1-MMP mAb or HYNIC-anti-MT1-MMP mAb divided by the median fluorescence intensity of negative control IgG. This was used as an index of immunoreactivity of anti-MT1-MMP mAb and HYNIC-anti-MT1-MMP mAb.

In Vitro Stability of ^{99m}Tc-Anti-MT1-MMP mAb in Rodent Plasma ^{99m}Tc-Anti-MT1-MMP mAb (30 μ l) was added to rat ($n=4$) or mouse ($n=3$) plasma (270 μ l) collected from female Sprague-Dawley (SD) rats or female C3H/He mice. Plasma samples were incubated at 37 $^{\circ}$ C for 48 h. After incubation, 50 to 100 μ l aliquots of samples were drawn and radioactivity was analyzed by size-exclusion chromatography with a PD-10 column using 0.05 M PBS (pH 7.0).

Preparation of Tumor-Bearing Animals Female SD rats (8 weeks old) and female C3H/He mice (5 weeks old), supplied by Japan SLC, Inc. (Hamamatsu, Japan), were housed under a 12-h light/12-h dark cycle and given free access to food and water. The animal experiments in this study were conducted in accordance with institutional guidelines and approved by the Kyoto University Animal Care Committee, Japan.

Rat breast carcinoma cells (Walker-256 and MRMT-1) and mouse breast carcinoma cells (FM3A) were supplied by the Cell Resource Center for Biomedical Research, Tohoku University and Health Science Research Resources Bank (HSRRB) (Osaka, Japan). Cells were cultured in RPMI1640 medium supplemented with 10% fetal bovine serum at 37 $^{\circ}$ C

in a humidified atmosphere containing 5% CO₂ and 95% air.

Walker-256 and MRMT-1 cells were suspended in 0.01 M PBS (pH 7.4) followed by subcutaneous inoculation into the right hind flank of rats (10⁶ cells/100 μ l PBS/rat). FM3A cells were suspended in PBS followed by subcutaneous inoculation into the right hind leg of mice (5 \times 10⁶ cells/100 μ l PBS/mouse). Tumor volume was estimated by [(length) \times (width)²]/2¹⁴⁾ over a 10- to 14-d tumor growth period. The average size of the tumors was 860 \pm 960 mm³, 790 \pm 280 mm³ and 230 \pm 170 mm³ for Walker-256, MRMT-1 and FM3A, respectively, on the day before the biodistribution studies.

Western Blotting Cell lysates were prepared from Walker-256, MRMT-1 and FM3A cells by homogenization in passive lysis buffer (E194A, Promega, WI, U.S.A.) containing protease inhibitor (P8340, Sigma Aldrich Co., MO, U.S.A.). Protein content of the lysates was determined by the BCA method and 5.0 μ g of protein/lane was subjected to electrophoresis on 5–20% sodium dodecyl sulfate (SDS)-polyacrylamide gels followed by transfer to polyvinylidene difluoride membranes. After blocking with Blocking One (03953-95, Nacalai Tesque, Inc., Kyoto, Japan), membranes were incubated with anti-MT1-MMP antibody followed by horseradish peroxidase-conjugated goat anti-mouse IgG₃ antibody. Bands were visualized by ECL plus Western Blotting Detection System (RPN2132, GE Healthcare, U.K.) with a Luminocapture instrument (BIO-RAD Laboratories, Osaka, Japan). Immunoblotting for β -actin was used as a protein loading control.

In Vivo Biodistribution Study Animals were divided into 5 groups ($n=3$ –4 each) for 5 time points with approximately equal distribution of tumor sizes on the day before the study. Animals were fasted for 6 h before administration of radiopharmaceutical. At 1, 3, 6, 24, and 48 h after intravenous administration of ^{99m}Tc-anti-MT1-MMP mAb (3.4 \pm 0.9 MBq, 50 μ g/200 μ l PBS for rats, 50 μ g/100 μ l PBS for mice), animals were euthanized. The blood, heart, lung, liver, kidney, stomach, intestine, spleen, pancreas, brain, muscle and tumor were excised, weighed and counted for radioactivity with a NaI well-type scintillation counter (1470 WIZARD, PerkinElmer Japan Co., Osaka, Japan). In addition, biodistribution of ^{99m}Tc-negative control mAb was evaluated in MRMT-1 implanted rats in a similar way.

Radiation Absorbed Dose For estimating radiation absorbed doses, source organ residence times were determined by calculating the area under non-decay-corrected time-activity curves generated for each organ using averaged biodistribution data. Projected radiation absorbed doses for humans were made by assuming that the metabolism rates and pharmacokinetics of ^{99m}Tc-anti-MT1-MMP mAb in humans and rodents are equivalent, as previously reported.¹⁵⁾ Absorbed doses and effective dose were estimated with a standard quantitation platform Organ Level Internal Dose Assessment (OLINDA; Vanderbilt University).¹⁶⁾

RESULTS

In Vitro Studies Indices of immunoreactivity evaluated by flow cytometry analyses were 5.83 \pm 3.05 and 6.13 \pm 2.73 for the HYNIC-anti-MT1-MMP mAb and anti-MT1-MMP mAb, respectively. This showed that the HYNIC-anti-MT1-




Fig. 1. A Representative FACS Overlay Histogram of Binding of Anti-MT1-MMP mAb, HYNIC-Anti-MT1-MMP mAb and Negative Control IgG₃ to Mouse Macrophages (RAW 264.7)

Immunoreactivities of anti-MT1-MMP mAb and HYNIC-anti-MT1-MMP mAb were evaluated with the median fluorescence intensity ratio compared to negative control mouse IgG₃.




Fig. 2. (A) Western Blot Analyses of MT1-MMP (Pro- and Active-Forms) and β -Actin Expression in Walker-256, MRMT-1 and FM3A Cells and (B) Densitometry Analyses of the Bands in (A)

The levels of pro- and active-MT1-MMP were normalized to the level of β -actin protein.

MMP mAb retained 93% immunoreactivity of the anti-MT1-MMP mAb (Fig. 1). Forty-eight hours after initiation of incubation in rat and mouse plasmas at 37 °C, more than 92% of ^{99m}Tc-anti-MT1-MMP mAb remained in an unchanged form.

Western Blotting Cell lysates were subjected to Western blot analysis to examine the quantities of MT1-MMP (Fig. 2). Expression of both the pro- (63 kDa) and active- (58 kDa) forms of MT1-MMP protein was detected in Walker-256, MRMT-1 and FM3A cells. When normalized to the level of β -actin protein, as represented in Fig. 2B, similar expression levels were confirmed.

In Vivo Biodistribution Studies Results of *in vivo* biodistribution studies are summarized in Table 1 (Walker-256 and MRMT-1) and Table 2 (FM3A). In tumors, radioactivity increased in a time-dependent manner and at 24 h post-injection, 3 to 5 times higher accumulations were achieved than those at 1 h. Values in % dose/g at 1 and 24 h post-injection were 0.41 ± 0.15 and 2.04 ± 0.65 in Walker-256, 0.44 ± 0.12 and 1.42 ± 0.08 in MRMT-1, and 2.63 ± 0.59 and 15.00 ± 0.48 in FM3A, respectively. Radioactivity in the kidneys was rather high among organs in all three tumor animal models. Values in % dose/g in the kidneys were 3.23 ± 0.21

Table 1. Biodistribution of Radioactivity after Injection of ^{99m}Tc-Anti-MT1-MMP mAb in SD Rats Bearing Walker-256 or MRMT-1 Rat Breast Tumors^{a)}

Tissue	Time after injection				
	1 h	3 h	6 h	24 h	48 h
	Walker-256				
Blood	5.28 (0.52)	4.75 (0.52)	4.43 (0.77)	2.07 (0.43)	1.22 (0.15)
Heart	0.75 (0.08)	0.84 (0.11)	0.86 (0.08)	0.60 (0.16)	0.44 (0.05)
Lung	2.51 (0.27)	1.48 (0.13)	1.90 (0.33)	1.16 (0.24)	1.22 (0.73)
Liver	1.89 (0.28)	2.28 (0.15)	2.59 (0.19)	2.09 (0.32)	2.05 (0.26)
Kidney	1.67 (0.10)	2.00 (0.19)	2.12 (1.18)	2.84 (0.48)	3.23 (0.21)
Intestine	0.25 (0.03)	0.46 (0.07)	0.57 (0.11)	0.45 (0.15)	0.28 (0.03)
Pancreas	0.41 (0.10)	0.35 (0.17)	0.31 (0.10)	0.52 (0.29)	0.45 (0.08)
Spleen	1.60 (0.06)	1.66 (0.15)	1.80 (0.30)	1.86 (0.28)	1.68 (0.31)
Muscle	0.07 (0.01)	0.07 (0.02)	0.07 (0.02)	0.11 (0.05)	0.11 (0.06)
Brain	0.11 (0.01)	0.10 (0.02)	0.10 (0.02)	0.06 (0.01)	0.03 (0.00)
Tumor	0.41 (0.15)	0.71 (0.13)	1.09 (0.31)	2.04 (0.65)	1.76 (0.31)
Stomach ^{b)}	0.86 (0.10)	1.18 (0.10)	1.20 (0.41)	0.72 (0.29)	0.38 (0.11)
Urine ^{b)}				17.62 (1.00)	24.97 (1.05)
Feces ^{b)}				5.29 (1.74)	8.94 (2.11)
Tumor/blood	0.08 (0.03)	0.15 (0.04)	0.24 (0.06)	0.97 (0.17)	1.46 (0.26)
Tumor/ muscle	5.79 (1.99)	10.67 (1.37)	16.69 (3.20)	21.20 (5.48)	19.99 (10.66)
	MRMT-1				
Blood	4.90 (0.42)	3.94 (0.21)	3.77 (0.30)	1.66 (0.16)	0.94 (0.09)
Heart	0.88 (0.06)	0.85 (0.19)	0.88 (0.14)	0.55 (0.06)	0.36 (0.06)
Lung	1.51 (0.11)	1.72 (0.47)	1.56 (0.28)	1.08 (0.11)	0.71 (0.03)
Liver	1.43 (0.13)	1.50 (0.09)	1.71 (0.14)	1.13 (0.15)	1.21 (0.18)
Kidney	1.75 (0.11)	2.14 (0.29)	2.73 (0.06)	2.93 (0.15)	3.05 (0.29)
Intestine	0.26 (0.03)	0.39 (0.06)	0.61 (0.08)	0.26 (0.01)	0.20 (0.03)
Pancreas	0.30 (0.05)	0.22 (0.04)	0.30 (0.10)	0.32 (0.01)	0.21 (0.03)
Spleen	1.14 (0.18)	1.06 (0.11)	1.17 (0.04)	0.97 (0.12)	0.92 (0.08)
Muscle	0.08 (0.01)	0.06 (0.01)	0.05 (0.02)	0.09 (0.01)	0.07 (0.06)
Brain	0.12 (0.02)	0.08 (0.00)	0.08 (0.00)	0.04 (0.01)	0.03 (0.00)
Tumor	0.44 (0.12)	0.73 (0.11)	1.01 (0.19)	1.42 (0.08)	1.20 (0.15)
Stomach ^{b)}	0.36 (0.03)	0.43 (0.03)	0.69 (0.41)	0.52 (0.06)	0.25 (0.02)
Urine ^{b)}				12.08 (0.33)	16.76 (1.03)
Feces ^{b)}				2.40 (1.14)	4.71 (0.79)
Tumor/blood	0.09 (0.02)	0.18 (0.03)	0.27 (0.06)	0.86 (0.07)	1.28 (0.18)
Tumor/ muscle	5.85 (1.95)	12.49 (2.76)	20.75 (6.51)	16.74 (1.50)	16.79 (7.67)

a) Tissue radioactivity is expressed as % injected dose per gram. Each value represents the mean (\pm S.D.) for four animals at each interval. b) Expressed as % injected dose.

Table 2. Biodistribution of Radioactivity after Injection of ^{99m}Tc-Anti-MT1-MMP mAb in C3H/He Mice Bearing FM3A Mouse Breast Tumors^{a)}

Tissue	Time after injection				
	1 h	3 h	6 h	24 h	48 h
Blood	37.05 (2.09)	31.68 (4.75)	29.78 (4.19)	14.43 (0.83)	11.00 (0.10)
Heart	6.69 (0.61)	6.54 (2.39)	6.89 (0.89)	4.93 (0.29)	4.45 (0.47)
Lung	20.21 (4.11)	16.72 (0.58)	13.59 (1.55)	7.92 (1.32)	6.25 (0.60)
Liver	8.46 (1.39)	9.03 (0.84)	8.02 (0.70)	5.76 (0.42)	5.33 (0.40)
Kidney	9.01 (1.55)	10.75 (1.23)	10.63 (1.60)	8.20 (0.27)	8.80 (0.27)
Intestine	2.47 (0.49)	4.47 (0.80)	7.09 (0.94)	2.47 (0.32)	2.20 (0.30)
Pancreas	1.00 (0.15)	1.49 (0.13)	1.60 (0.51)	1.77 (0.15)	2.08 (0.22)
Spleen	7.27 (1.04)	7.09 (1.04)	6.10 (0.90)	5.66 (0.20)	6.57 (0.78)
Muscle	0.48 (0.05)	0.62 (0.04)	0.64 (0.29)	1.28 (0.39)	1.88 (0.39)
Brain	0.63 (0.21)	0.49 (0.10)	0.44 (0.06)	0.28 (0.02)	0.33 (0.01)
Tumor	2.63 (0.59)	4.10 (1.44)	5.97 (1.64)	15.00 (0.48)	16.99 (1.81)
Stomach ^{b)}	0.28 (0.04)	0.41 (0.09)	0.55 (0.17)	0.49 (0.02)	0.54 (0.10)
Urine ^{b,c)}				4.94	14.85
Feces ^{b,c)}				1.17	3.85
Tumor/blood	0.07 (0.02)	0.13 (0.04)	0.21 (0.07)	1.04 (0.06)	1.54 (0.17)
Tumor/muscle	5.42 (0.73)	6.58 (2.24)	9.83 (1.63)	12.37 (2.93)	9.39 (2.33)

a) Tissue radioactivity is expressed as % injected dose per gram. Each value represents the mean (±S.D.) for three (1 h) and four (3, 6, 24, 48 h) animals. b) Expressed as % injected dose. c) Calculated using summated radioactivity of four animals.

in Walker-256, 3.05±0.29 in MRMT-1 and 8.80±0.27 in FM3A, respectively, at 48 h post-injection. Other tissues, including the stomach, showed decreasing or constant radioactivity levels over time. Values in % dose in the stomach at 48 h post-injection were 0.38±0.11 in Walker-256, 0.25±0.02 in MRMT-1 and 0.54±0.10 in FM3A.

Tumor to blood (T/B) and tumor to muscle (T/M) ratios were calculated as indicators of availability of ^{99m}Tc-anti-MT1-MMP mAb for *in vivo* imaging. T/B ratios increased in a similar manner as the radioactivity in tumors. Ratios obtained were 1.46±0.26 in Walker-256, 1.28±0.18 in MRMT-1 and 1.54±0.17 in FM3A at 48 h post-injection. T/M ratios exhibited constantly high values after 6 h post-injection (16.69±3.20 in Walker-256, 20.75±6.51 in MRMT-1 and 9.83±1.63 in FM3A). T/B ratios of ^{99m}Tc-negative control mAb in MRMT-1 are also shown in Fig. 3. The values were 0.66±0.05 at 24 h and 0.81±0.09 at 48 h post-injection. The time-course of ^{99m}Tc-anti-MT1-MMP mAb was significantly higher than that of the ^{99m}Tc-negative control mAb by two factor factorial ANOVA assay (*p*<0.0001).

Radiation Absorbed Dose Radiation absorbed doses (μSv/MBq) were estimated using data of biodistribution studies with ^{99m}Tc-anti-MT1-MMP mAb (Table 3). The highest radiation dose was to the kidneys, followed by the liver, the intestine and the spleen. The effective dose was 4.4 to 5.0 μSv/MBq.




Fig. 3. Tumor to Blood (T/B) Ratios of Radioactivity after Administration of ^{99m}Tc-Anti-MT1-MMP mAb (Open Triangle) or ^{99m}Tc-Negative Control mAb (Close Triangle) to Rats Bearing MRMT-1 Breast Tumors

Error bars represent standard deviations. Two factor factorial ANOVA analyses determined significant difference between the time-courses of ^{99m}Tc-anti-MT1-MMP mAb and ^{99m}Tc-negative control mAb (*p*<0.0001).

Table 3. Radiation Dose (μSv/MBq) Estimated for ^{99m}Tc-Anti-MT1-MMP mAb

	Walker-256	MRMT-1	FM3A
Heart	5.7	6.0	6.3
Lung	5.8	5.1	7.2
Liver	23.8	16.8	12.4
Kidney	20.6	21.8	15.6
Intestine	11.5	12.3	12.5
Pancreas	6.9	6.1	6.0
Spleen	10.7	8.7	7.9
Muscle	1.5	1.8	2.2
Brain	0.5	0.8	1.2
Stomach	6.9	5.4	5.4
Red marrow	1.9	2.5	3.0
Osteogenic cells	3.3	5.4	7.1
Ovaries	3.2	4.2	4.9
Uterus	2.9	3.9	4.6
Total body	2.5	3.0	3.4
Effective dose	4.4	4.7	5.0
Effective dose equivalent	6.5	6.4	6.4

DISCUSSION

We prepared ^{99m}Tc-anti-MT1-MMP mAb with a sustained immunoreactivity comparable to anti-MT1-MMP mAb and high radiochemical purity, and evaluated its usefulness through biodistribution studies using breast tumor-implanted rodents. The effectiveness of ^{99m}Tc-anti-MT1-MMP mAb for detecting breast tumors expressing MT1-MMP, that is 'malignant tumors', was demonstrated since radioactivity in tumors and T/B and T/M ratios increased with time after administration of ^{99m}Tc-anti-MT1-MMP mAb in all three tumor models. T/B ratios of ^{99m}Tc-anti-MT1-MMP mAb were significantly higher than those of the ^{99m}Tc-negative control mAb, indicating the specificity of ^{99m}Tc-anti-MT1-MMP mAb toward MT1-MMP. The moderate accumulation of ^{99m}Tc-negative control mAb in tumors could be due to the enhanced permeability and retention (EPR) effect, which is characterized by enhanced permeability of tumor vasculatures and little lymphatic recovery.¹⁷⁾ Importantly, other tissues including the stomach showed a concomitant decrease

in radioactivity over time. In addition, the biodistribution results exhibiting high accumulation in tumors also indicated the suitability of this antibody for radioimmunotherapy. Together, this suggests that the radiolabeled antibody is a promising probe for *in vivo* nuclear medical imaging, such as single photon emission computed tomography (SPECT), for future diagnoses of breast tumors. Although further investigations are needed for more sensitive detection, it should be emphasized that this is the first report of development of an *in vivo* probe targeted to MT1-MMP. Also, the development of such an imaging agent provides a strong tool for clarification of the roles of MT1-MMP on tumors *in vivo*, which may lead to development of a novel pharmaceutical.

In the present study, technetium-99m was used to label anti-MT1-MMP mAb because of its optimal characteristics for *in vivo* imaging in clinical settings. This then led to the selection of HYNIC as a bifunctional chelating agent since it has high stability by coordination with Tc-99m and two molecules of tricine.¹¹⁾ As expected, ^{99m}Tc-anti-MT1-MMP mAb was stable in plasma. Furthermore, the low radioactivity detected in the stomach indicated the *in vivo* stability of ^{99m}Tc-anti-MT1-MMP mAb against dissociation of Tc-99m from HYNIC and oxygenation to ^{99m}Tc pertechnetate. If dissociation had occurred, ^{99m}Tc pertechnetate would have been taken up by the epithelial cells that line the mucosal surface of the stomach *via* the sodium iodide symporter system^{18,19)} and the radioactivity detected would have been much higher. The high stability of the radioligand was essential for further evaluation.

Relatively slow washout of radioactivity from the blood might be a drawback for the imaging ability of ^{99m}Tc-anti-MT1-MMP mAb. Previous researchers reported that this could be overcome by fragmentation of the antibody or synthesis of small-molecule derivatives.^{20,21)} In addition, moderate radioactivities in the kidneys, liver and spleen were observed in biodistribution studies that were not due to MT1-MMP expression.⁴⁾ However, these radioactivities might not affect the imaging quality of breast tumors. To estimate the effective dose of the ^{99m}Tc-anti-MT1-MMP mAb, which is an estimate of the stochastic effect that a non-uniform radiation dose has on a human, the OLINDA estimation gave a maximum value of 5.0 μ Sv/MBq. This value is similar to the average effective dose in nuclear medicine,²²⁾ indicating that the use of ^{99m}Tc-anti-MT1-MMP mAb may be acceptable for *in vivo* imaging in humans.

Several MMP imaging probes have been developed for detecting states of MMP-dependent diseases such as cancer, atherosclerosis, stroke, and other pathophysiologies. Among them, radiolabeled broad-spectrum MMP inhibitors (MPIs) have been mostly investigated during *in vitro* and *in vivo* evaluations.^{23,24)} Some of these radiolabeled MPIs exhibited promising pharmacodynamics partly due to their low molecular weight. However, these small molecular probes mainly recognize soluble MMPs including MMP-2, -3, -9, and -13, while our ^{99m}Tc-anti-MT1-MMP mAb recognizes a membrane-bound MMP, MT1-MMP. As a target molecule of a radiolabeled probe, it is important to be localized at the site of malignancy in order to obtain clear images that can be readily compared to anatomical information. Background levels can become elevated in cases where target molecules are secreted to the surrounding tissues or bodily fluids including

blood. Therefore, it may be advantageous to utilize MT1-MMP rather than soluble MMPs as a target molecule for detecting cancer malignancy. In addition, the use of a monoclonal antibody and/or an antibody derivative as a fundamental part of radiolabeled probe is significantly superior to radiolabeled MPIs for strict targeting to a specific MMP.

In this study, three breast tumor cell lines, MRMT-1, Walker 256 and FM3A, from two different species were used in order to evaluate the prevalence of the radiolabeled probe. MRMT-1 is a rat mammary gland carcinoma cell line generally used for studies of bone pain,²⁵⁾ where bones inoculated with these cells showed infiltration of bone marrow spaces by malignant tumors.²⁶⁾ Walker 256 is also a rat breast carcinoma cell line used in a variety of cancer studies. As previously reported in a histological study,²⁷⁾ these cells show several ultrastructural features that typically designate malignancy. FM3A is a murine mammary carcinoma cell line especially used in studies on hypoxia in tumors,²⁸⁾ where cells showed high radioresistance.²⁹⁾ Therefore, all these cell lines give rise to malignant tumors and, as expected, the expression of MT1-MMP protein was comparable in each. Similar accumulations of radioactivity in tumors were found in the biodistribution experiments.

It is known that MT1-MMP is subject to recycling.³⁰⁾ MT1-MMP is produced inside the cell by cleavage of the pro-domain of pro-MT1-MMP by furin, transited to the cell membrane, dimerized, followed by complex formation with TIMP-2 to activate pro-MMP2, and finally internalized into the cell. Dimerization of MT1-MMPs occurs by interaction of the hemopexin-like domains, a region between the transmembrane domain and catalytic domain, of two separate molecules of MT1-MMP.³¹⁾ The epitope of the antibody used in this study was in the hemopexin-like domain so that reactions between the antibody and MT1-MMP, and between two molecules of MT1-MMP, could potentially compete for each other on the cell surface. Although it was not elucidated whether this competition would affect the results, providing that it does occur *in vivo* like pertuzumab,³²⁾ imaging efficiency may be further improved using an alternative antibody whose epitope is in a different domain of MT1-MMP.

The amino acid sequences of MT1-MMP protein are well preserved among species, including mouse, rat, rabbit and human.⁹⁾ The antibody used here was an anti-human MT1-MMP mouse monoclonal antibody IgG₃, though results were obtained in a rodent animal model in this study. In addition, this antibody is suited for detection of human MT1-MMP by preliminary Western blot analysis using lysates from human breast cancer cells (MDA-MB-231) (data not shown). Thus, the preferable outcomes reported for rodents might be easily translated to a clinical situation, after the antibody is optimally humanized to lose immunogenicity and endure metabolism in the body.

MT1-MMP is reported to experience shedding by other proteases on the cell surface leading to soluble MT1-MMP secreted into the blood.³³⁾ Although a variety of forms of soluble MT1-MMP have been reported due to differences in the position of cleavage,³⁴⁾ it is unclear whether the antibody used in this study would react with soluble MT1-MMP in the blood. Since the biodistribution experiments of ^{99m}Tc-anti-MT1-MMP mAb showed a normal, or rather fast, clearance from the body, soluble MT1-MMP in the blood might not af-

fect the results.


CONCLUSION

^{99m}Tc -anti-MT1-MMP mAb accumulated in malignant tumors of all three animal models with a low effective dose, while radioactivity disappeared in non-targeted organs. The results suggest that the ^{99m}Tc -anti-MT1-MMP mAb is a promising probe for *in vivo* nuclear medical imaging for future diagnosis of breast tumors.

Acknowledgments This study was supported by Grants-in-Aid for Scientific Research and by the 21st Century Center of Excellence Programs at Kyoto University "Knowledge Information Infrastructure for Genome Science" from the Ministry of Education, Culture, Sports, Science and Technology of Japan. Part of this study was conducted as part of the project, "R&D of Molecular Imaging Equipment for Malignant Tumor Therapy Support," supported by the New Energy and Industrial Technology Development Organization (NEDO) of Japan.


REFERENCES

- DeNardo S. J., *Semin. Nucl. Med.*, **35**, 143—151 (2005).
- Slamon D. J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L., *N. Engl. J. Med.*, **344**, 783—792 (2001).
- Deryugina E. I., Quigley J. P., *Cancer Metastasis Rev.*, **25**, 9—34 (2006).
- Sato H., Takino T., Okada Y., Cao J., Shinagawa A., Yamamoto E., Seiki M., *Nature* (London), **370**, 61—65 (1994).
- Mori H., Tomari T., Koshikawa N., Kajita M., Itoh Y., Sato H., Tojo H., Yana I., Seiki M., *EMBO J.*, **21**, 3949—3959 (2002).
- Jones J. L., Glynn P., Walker R. A., *J. Pathol.*, **189**, 161—168 (1999).
- Knauper V., Bailey L., Worley J. R., Soloway P., Patterson M. L., Murphy G., *FEBS Lett.*, **532**, 127—130 (2002).
- Chen P. S., Zhai W. R., Zhou X. M., Zhang J. S., Zhang Y. E., Ling Y. Q., Gu Y. H., *World J. Gastroenterol.*, **7**, 647—651 (2001).
- Sato T., del Carmen Ovejero M., Hou P., Heegaard A. M., Kumegawa M., Foged N. T., Delaïsse J. M., *J. Cell Sci.*, **110**, 589—596 (1997).
- Jemal A., Murray T., Samuels A., Tiwari R. C., Ghafoor A., Feuer E. J., Thun M. J., *CA Cancer J. Clin.*, **55**, 10—30 (2005).
- Abrams M. J., Juweid M., tenKate C. I., Schwartz D. A., Hauser M. A., Gaul F. E., Fuccello A. J., Rubin R. H., Strauss H. W., Fischman A. J., *J. Nucl. Med.*, **31**, 2022—2028 (1990).
- Smith P. K., Krohn R. I., Hermanson G. T., Mallia A. K., Gartner F. H., Provenzano M. D., Fujimoto E. K., Goeke N. M., Olson B. J., Klenk D. C., *Anal. Biochem.*, **150**, 76—85 (1985).
- Larsen S. K., Solomon H. F., Caldwell G., Abrams M. J., *Bioconjug. Chem.*, **6**, 635—638 (1995).
- Zhang Y., Wang C., Sun M., *Biochem. Biophys. Res. Commun.*, **325**, 1240—1245 (2004).
- Cai W., Ebrahimnejad A., Chen K., Cao Q., Li Z. B., Tice D. A., Chen X., *Eur. J. Nucl. Med. Mol. Imaging*, **34**, 2024—2036 (2007).
- Stabin M. G., Sparks R. B., Crowe E., *J. Nucl. Med.*, **46**, 1023—1027 (2005).
- Matsumura Y., Maeda H., *Cancer Res.*, **46**, 6387—6392 (1986).
- Ekblad T., Tran T., Orlova A., Widstrom C., Feldwisch J., Abrahmsen L., Wennborg A., Karlstrom A. E., Tolmachev V., *Eur. J. Nucl. Med. Mol. Imaging*, **35**, 2245—2255 (2008).
- Kiratli P. O., Aksoy T., Bozkurt M. F., Orhan D., *Ann. Nucl. Med.*, **23**, 97—105 (2009).
- Holliger P., Hudson P. J., *Nat. Biotechnol.*, **23**, 1126—1136 (2005).
- Wong J. Y., Chu D. Z., Williams L. E., Yamauchi D. M., Ikle D. N., Kwok C. S., Liu A., Wilczynski S., Colcher D., Yazaki P. J., Shively J. E., Wu A. M., Raubitschek A. A., *Clin. Cancer Res.*, **10**, 5014—5021 (2004).
- Ueda M., Iida Y., Mukai T., Mamede M., Ishizu K., Ogawa M., Magata Y., Konishi J., Saji H., *Ann. Nucl. Med.*, **18**, 337—344 (2004).
- Wagner S., Breyholz H. J., Faust A., Holtke C., Levkau B., Schober O., Schafers M., Kopka K., *Curr. Med. Chem.*, **13**, 2819—2838 (2006).
- Wagner S., Breyholz H. J., Holtke C., Faust A., Schober O., Schafers M., Kopka K., *Appl. Radiat. Isot.*, **67**, 606—610 (2009).
- Ogawa K., Mukai T., Asano D., Kawashima H., Kinuya S., Shiba K., Hashimoto K., Mori H., Saji H., *J. Nucl. Med.*, **48**, 122—127 (2007).
- Medhurst S. J., Walker K., Bowes M., Kidd B. L., Glatt M., Muller M., Hattenberger M., Vaxelaire J., O'Reilly T., Wotherspoon G., Winter J., Green J., Urban L., *Pain*, **96**, 129—140 (2002).
- Chew E. C., *Experientia*, **32**, 1192—1194 (1976).
- Saitoh J., Sakurai H., Suzuki Y., Muramatsu H., Ishikawa H., Kitamoto Y., Akimoto T., Hasegawa M., Mitsuhashi N., Nakano T., *Int. J. Radiat. Oncol. Biol. Phys.*, **54**, 903—909 (2002).
- Masunaga S., Ono K., Suzuki M., Kinashi Y., Takagaki M., *Int. J. Radiat. Oncol. Biol. Phys.*, **49**, 1361—1368 (2001).
- Wang X., Ma D., Keski-Oja J., Pei D., *J. Biol. Chem.*, **279**, 9331—9336 (2004).
- Itoh Y., Takamura A., Ito N., Maru Y., Sato H., Suenaga N., Aoki T., Seiki M., *EMBO J.*, **20**, 4782—4793 (2001).
- Sakai K., Yokote H., Murakami-Murofushi K., Tamura T., Saijo N., Nishio K., *Cancer Sci.*, **98**, 1498—1503 (2007).
- Ren X. H., Peng X. D., Wu X. P., Liao E. Y., Sun Z. Q., *Clin. Chim. Acta*, **390**, 44—48 (2008).
- Toth M., Hernandez-Barrantes S., Osenkowski P., Bernardo M. M., Gervasi D. C., Shimura Y., Meroueh O., Kotra L. P., Galvez B. G., Arroyo A. G., Mobashery S., Fridman R., *J. Biol. Chem.*, **277**, 26340—26350 (2002).



Contents lists available at ScienceDirect

Biochemical and Biophysical Research Communications

journal homepage: www.elsevier.com/locate/ybbrc

GLP-1 receptor antagonist as a potential probe for pancreatic β -cell imaging

Eri Mukai^{a,b}, Kentaro Toyoda^a, Hiroyuki Kimura^c, Hidekazu Kawashima^d, Hiroyuki Fujimoto^{a,b}, Masashi Ueda^e, Takashi Temma^c, Konomu Hirao^f, Kenji Nagakawa^f, Hideo Saji^c, Nobuya Inagaki^{a,g,*}

^a Department of Diabetes and Clinical Nutrition, Graduate School of Medicine, Kyoto University, Kyoto, Japan

^b Japan Association for the Advancement of Medical Equipment, Tokyo, Japan

^c Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan

^d Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan

^e Radioisotopes Research Laboratory, Kyoto University Hospital, Faculty of Medicine, Kyoto University, Kyoto, Japan

^f Research & Development Division, Arkray, Inc., Kyoto, Japan

^g CREST of Japan Science and Technology Cooperation (JST), Kyoto, Japan

ARTICLE INFO

Article history:

Received 2 September 2009

Available online xxx

Keywords:

Glucagon-like peptide-1
Glucagon-like peptide-1 receptor
Exendin-4
Exendin(9-39)
 β -Cell imaging
Islet imaging
Molecular imaging
 β -Cell mass
Diabetes

ABSTRACT

We examined exendin(9-39), an antagonist of glucagon-like peptide-1 (GLP-1) receptor (GLP-1R), as a potential probe for imaging of pancreatic β -cells. To evaluate *in vitro* receptor specificity, binding assay was performed using dispersed mouse islet cells. Binding assay showed competitive inhibition of [¹²⁵I]BH-exendin(9-39) binding by non-radioactive exendin(9-39). To assess *in vivo* selectivity, the bio-distribution was evaluated by intravenous administration of [¹²⁵I]BH-exendin(9-39) to mice. Radioactivity of harvested pancreas reached highest levels at 60 and 120 min among organs examined except lung. Pre-administration of excess non-radioactive exendin(9-39) remarkably and specifically blocked the radioactivity of pancreas. After [¹²⁵I]BH-exendin(9-39) injection into transgenic mice with pancreatic β -cells expressing GFP, fluorescent and radioactive signals of sections of pancreas were evaluated with an image analyzer. Imaging analysis showed that the fluorescent GFP signals and the radioactive signals were correspondingly located. Thus, the GLP-1R antagonist exendin(9-39) may serve as a useful probe for pancreatic β -cell imaging.

© 2009 Published by Elsevier Inc.

Introduction

Type 1 diabetes is an autoimmune disease in which the pancreatic β -cells are almost destroyed, which leads to loss of endogenous insulin secretion. Insulin therapy is therefore required for survival in subjects with type 1 diabetes [1]. Type 2 diabetes is characterized by impaired insulin secretion and insulin resistance, and the pathogenesis is well known to be dependent on a reduction in β -cell function [2]. While a decrease in β -cell mass has been reported in American and Asian type 2 diabetic subjects compared with non-diabetic subjects [3–5], the decrease is small at onset in European subjects, suggesting that the decrease might occur only after onset of the disease [6]. It is therefore unknown whether a decrease in β -cell mass contributes to the development of hyperglycemia that leads to type 2 diabetes. Thus, accurately measuring changes in β -cell mass *in vivo* during diabetes progression is important not only for understanding the pathogenesis but also for facilitating early diagnosis and developing improved treatments for both type 1 and type 2 diabetes.

However, it is difficult to identify islets ranging in size from 50–500 μ m in diameter and scattered throughout the pancreas, which is surrounded by abdominal organs. To quantify β -cell mass non-invasively, appropriate probes that can specifically bind to pancreatic β -cells are required. There are previous reports using probes targeting the proteins in β -cells, including sulfonylurea receptor 1 (SUR1) and monoamine transporter 2 (VMAT2) for positron emission tomography (PET) imaging [7]. However, ideal probes for accurate and non-invasive imaging for pancreatic β -cells have not yet been developed.

Glucagon-like peptide 1 (GLP-1) is the incretin peptide released from the intestine in response to nutrient ingestion to augment glucose-induced insulin secretion from pancreatic β -cells through binding to the GLP-1 receptor (GLP-1R) [8,9]. Since GLP-1R is expressed highly in islets, especially on β -cells in pancreas, the ligands of GLP-1R might well be ideal probes for pancreatic β -cell imaging. Because native GLP-1 is degraded rapidly by dipeptidyl peptidase-IV (DPP-IV) distributed throughout the body, DPP-IV-resistant agonistic or antagonistic ligands of GLP-1R [10,11] are preferable to GLP-1 for use as an imaging probe.

In the present study, specific imaging of pancreatic β -cells targeting GLP-1R was evaluated using its antagonist, exendin(9-39), radiolabeled with [¹²⁵I]-Bolton-Hunter reagent at lysine residues.

* Corresponding author. Address: Department of Diabetes and Clinical Nutrition, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan. Fax: +81 75 771 6601.
E-mail address: inagaki@metab.kuhp.kyoto-u.ac.jp (N. Inagaki).

86 **Materials and methods**

87 *Radiolabeling of exendin(9-39).* [125 I]-Bolton-Hunter-labeled exendin(9-39) ([125 I]-BH exendin(9-39)) was purchased from Perkin-Elmer (Waltham, MA).

90 *Animals.* Six-week-old male ddY mice were obtained from Shimizu Co. (Kyoto, Japan). Transgenic mice expressing green fluorescent protein (GFP) under control of the mouse insulin I gene promoter (MIP) (MIP-GFP mice) were maintained on a C57BL/6 background [12]. Animal care and procedures were approved by the Animal Care Committee of Kyoto University.

96 *Binding assay.* The displacing effect of exendin(9-39) on GLP-1R binding was assessed using dispersed islet cells as described previously [13]. Pancreatic islets were isolated from male ddY mice by a collagenase digestion technique [14]. Isolated islets were dispersed using 0.05% trypsin/0.53 mM EDTA (Invitrogen, Carlsbad, CA) and PBS. Islet cells were incubated with [125 I]BH-exendin(9-39) (0.1 μ Ci) in 1 ml of buffer containing 20 mM HEPES (pH 7.4), 1 mM MgCl₂, 1 mg/ml bacitracin, and 1 mg/ml BSA for 1 h at room temperature in the presence of varying concentrations of non-radioactive exendin(9-39). Binding was terminated by rapid filtration through Whatman GF/C filters (24 mm) followed by washing three times with 5 ml of ice-cold PBS. The radioactivity of filters was measured in a γ -counter. Results were expressed as the percent radioactivity of bound [125 I]BH-exendin(9-39) that remained after addition of non-radioactive compound.

111 *Biodistribution experiments.* Biodistribution studies of [125 I]BH-exendin(9-39) were performed in male ddY mice. [125 I]BH-exen-




Fig. 1. Binding assay analysis of [125 I]BH-exendin(9-39) using mouse pancreatic islet cells. Competitive inhibition of [125 I]BH-exendin(9-39) binding by non-radioactive exendin(9-39) is shown. Values are expressed as means \pm SD of the percent radioactivity of bound [125 I]BH-exendin(9-39) that remained after addition of indicated concentrations of non-radioactive exendin(9-39) ($n = 4$).

113 din(9-39) (1 μ Ci) was administered by tail vein injection. At 15, 114 30, 60, and 120 min after administration, the mice were sacrificed 115 by exsanguination under anesthesia. Selected organs and blood




Fig. 2. Tissue distribution of [125 I]BH-exendin(9-39) in mice. (A) Time course of tissue distribution of [125 I]BH-exendin(9-39). Right graph shows tissue distribution without lung. (B) Blocking of tissue distribution at 120 min after [125 I]BH-exendin(9-39) injection by pre-administration of excess non-radioactive exendin(9-39). Values are expressed as means \pm SD of the percent radioactivity of injected [125 I]BH-exendin(9-39) per gram of organ weight ($n = 5$). $P < 0.001$ vs. control.

116 were harvested and weighed, and the radioactivities were measured with a γ -counter. In a blocking study, excess non-radioactive exendin(9-39) (50 μ g) in 100 μ l of saline was administered 30 min before the [125 I]BH-exendin(9-39) injection. Results were expressed as percent radioactivity of injected [125 I]BH-exendin(9-39) per gram of organ weight.

122 *Two-dimensional imaging analysis.* After intravenous administration of [125 I]BH-exendin(9-39) to male MIP-GFP mice, the pancreas was harvested and cut in several pieces. Each piece was put on slide glass and pressed with a cover glass. Signals of fluorescence and radioactivity (autoradiography) of sections of pancreas were evaluated with an image analyzer (Typhoon 9410; GE Healthcare, Buckinghamshire, UK). The fluorescent and radioactive intensity of each section was analyzed with ImageQuant TL software with resolution of 25 and 10 μ m per pixel, respectively (GE Healthcare).

131 *Statistical analysis.* Data are expressed as means \pm SD. Statistical significance of difference was evaluated by unpaired alternate Welch *t* test. $P < 0.05$ was considered significant.

134 Results and discussion

135 We first examined binding specificity of exendin(9-39) to pancreatic β -cell membrane *in vitro*. Binding assay analysis using mouse pancreatic islet cells showed competitive inhibition of [125 I]BH-exendin(9-39) binding by non-radioactive exendin(9-39) with a $\log IC_{50}$ of -8.84 ± 0.18 , similarly to the findings in a previous report [15], indicating that exendin(9-39) binds to those cells specifically (Fig. 1).

142 To examine selectivity of exendin(9-39) to pancreas *in vivo*, we performed biodistribution studies in mice. Radioactivities of selected organs were measured 15, 30, 60, and 120 min after intravenous administration of [125 I]BH-exendin(9-39) (1 μ Ci). The radioactivity of lung was highest at each time point (Fig. 2A, left panel). Radioactivity of pancreas increased with time and was highest at 60 and 120 min among organs examined excepting lung, and rapid and high binding by liver was observed (Fig. 2A, right panel). To determine whether the binding was specific, we performed blocking study. Pre-administration of excess non-radioactive exendin(9-39) (50 μ g) significantly blocked the radioactivities of pancreas and lung to 17.8% and 8.8% of control, respectively, 120 min after [125 I]BH-exendin(9-39) injection (Fig. 2B), demonstrating that [125 I]BH-exendin(9-39) specifically binds to its receptor in these organs. The binding in other organs such as liver was not blocked by excess non-radioactive exendin(9-39).

158 To confirm high binding of exendin(9-39) in β -cells, we performed [125 I]BH-exendin(9-39) injection in MIP-GFP mice specifically expressing GFP in pancreatic β -cells and imaging analysis of sections of the pancreas removed 60 or 120 min after [125 I]BH-exendin(9-39) injection. As shown in Fig. 3A, fluorescent GFP signals were observed in the pancreatic sections of MIP-GFP mice with an image analyzer. Localization of the detected radioactive signals corresponded well to that of the GFP signals, indicating specific high binding of exendin(9-39) in pancreatic β -cells. The intensity of the fluorescent signals of each section also correlated with that of the radioactive signals (Fig. 3B).

169 Studies for detecting β -cell mass have been performed using probes targeting various β -cell-specific molecules, among which GLP-1R appears promising [7]. *In vivo* imaging of GLP-1R-positive tissues using diethylenetriaminepentaacetic acid (DTPA)-conjugated exendin-4, the GLP-1R agonist, was recently reported [16]. The biodistribution examinations showed its specific binding not only to pancreas and lung but also to stomach. Although pancreas and lung as well as pituitary and adrenals were detected in single photon emission computed tomography (SPECT) imaging, it was not determined whether the probe was confined to β -cells due to

179 the low resolution of the imaging apparatus. In the present study, we found that exendin(9-39), an antagonistic ligand of GLP-1R, has high specificity not only to pancreas but also to β -cells in pancreas, suggesting that β -cell mass can be evaluated. High binding of the probe in lung, as previously reported [16], does not affect analysis of islets because lung is an extra-abdominal organ, for which imaging such as SPECT is required.

186 A better understanding of the relationship between β -cell mass, β -cell function, and glucose homeostasis by precise measurement of β -cell mass should provide important information on not only for early diagnosis and treatment but also for development of new therapies for intervention strategies. Several tests are presently available for evaluation of β -cell function [17]. In contrast,




Fig. 3. Imaging analysis of pancreas sections of [125 I]BH-exendin(9-39)-injected MIP-GFP mice. (A) Representative fluorescent signals (left panels) and radioactive signals (right panels) of pancreas sections at 60 min (a) and 120 min (b) after [125 I]BH-exendin(9-39) injection. Bars represent 1 cm. (B) Correlation of the fluorescent and radioactive intensity. The signal intensity in whole area of each of the nine sections of pancreas harvested 120 min after [125 I]BH-exendin(9-39) injection was analyzed with ImageQuant TL software.

192 measurement of β -cell mass is presently possible only by autopsy.
 193 It has recently been reported that antagonistic probes as well as
 194 agonistic probes are useful for molecular imaging by targeting pep-
 195 tide receptors [18]. In the present study, we demonstrate for the
 196 first time that the GLP-1R antagonist exendin(9-39) is a potential
 197 probe for the imaging of pancreatic β -cells.

198 Acknowledgments

199 We thank Dr. M. Hara, University of Chicago, for generously
 200 providing us transgenic MIP-GFP mice. This work was supported
 201 by a Research Grant on Nanotechnical Medicine from the Ministry
 202 of Health, Labour, and Welfare of Japan, and by Scientific Research
 203 Grants from the Ministry of Education, Culture, Sports, Science, and
 204 Technology of Japan, and also by Kyoto University Global COE Pro-
 205 gram "Center for Frontier Medicine".

206 References

- 207 [1] W.V. Tamborlane, W. Bonfig, E. Boland, Recent advances in treatment of youth
 208 with type 1 diabetes: better care through technology, *Diabet. Med.* 18 (2001)
 209 864-870.
- 210 [2] L. Groop, Pathogenesis of type 2 diabetes: the relative contribution of insulin
 211 resistance and impaired insulin secretion, *Int. J. Clin. Pract. Suppl.* (2000) 3-13.
- 212 [3] H. Sakuraba, H. Mizukami, N. Yagihashi, R. Wada, C. Hanyu, S. Yagihashi, Reduced
 213 beta-cell mass and expression of oxidative stress-related DNA damage in the
 214 islet of Japanese type II diabetic patients, *Diabetologia* 45 (2002) 85-96.
- 215 [4] A.E. Butler, J. Janson, S. Bonner-Weir, R. Ritzel, R.A. Rizza, P.C. Butler, Beta-cell
 216 deficit and increased beta-cell apoptosis in humans with type 2 diabetes,
 217 *Diabetes* 52 (2003) 102-110.
- 218 [5] K.H. Yoon, S.H. Ko, J.H. Cho, J.M. Lee, Y.B. Ahn, K.H. Song, S.J. Yoo, M.I. Kang, B.Y.
 219 Cha, K.W. Lee, H.Y. Son, S.K. Kang, H.S. Kim, I.K. Lee, S. Bonner-Weir, Selective
 220 beta-cell loss and alpha-cell expansion in patients with type 2 diabetes
 221 mellitus in Korea, *J. Clin. Endocrinol. Metab.* 88 (2003) 2300-2308.
- [6] J. Rahier, Y. Guiot, R.M. Goebbels, C. Sempoux, J.C. Henquin, Pancreatic beta-
 cell mass in European subjects with type 2 diabetes, *Diabetes Obes. Metab.* 10
 (Suppl. 4) (2008) 32-42.
- [7] S. Schneider, Efforts to develop methods for in vivo evaluation of the native
 beta-cell mass, *Diabetes Obes. Metab.* 10 (Suppl. 4) (2008) 109-118.
- [8] L.L. Baggio, D.J. Drucker, Biology of incretins: GLP-1 and GIP, *Gastroenterology*
 132 (2007) 2131-2157.
- [9] J.J. Holst, The physiology of glucagon-like peptide 1, *Physiol. Rev.* 87 (2007)
 1409-1439.
- [10] J. Eng, W.A. Kleinman, L. Singh, G. Singh, J.P. Raufman, Isolation and
 characterization of exendin-4, an exendin-3 analogue, from *Heloderma*
suspectum venom. Further evidence for an exendin receptor on dispersed
 acini from guinea pig pancreas, *J. Biol. Chem.* 267 (1992) 7402-7405.
- [11] R. Goke, H.C. Fehmann, T. Linn, H. Schmidt, M. Krause, J. Eng, B. Goke, Exendin-
 4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist
 at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting
 beta-cells, *J. Biol. Chem.* 268 (1993) 19650-19655.
- [12] M. Hara, X. Wang, T. Kawamura, V.P. Bindokas, R.F. Dizon, S.Y. Alcoser, M.A.
 Magnuson, G.I. Bell, Transgenic mice with green fluorescent protein-labeled
 pancreatic beta-cells, *Am. J. Physiol. Endocrinol. Metab.* 284 (2003) E177-
 E183.
- [13] E. Mukai, H. Ishida, S. Kato, Y. Tsuura, S. Fujimoto, A. Ishida-Takahashi, M.
 Horie, K. Tsuda, Y. Seino, Metabolic inhibition impairs ATP-sensitive K+
 channel block by sulfonylurea in pancreatic beta-cells, *Am. J. Physiol.* 274
 (1998) E38-E44.
- [14] R. Sutton, M. Peters, P. McShane, D.W. Gray, P.J. Morris, Isolation of rat
 pancreatic islets by ductal injection of collagenase, *Transplantation* 42 (1986)
 689-691.
- [15] S. Al-Sabah, D. Donnelly, A model for receptor-peptide binding at the
 glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated
 ligands and receptors, *Br. J. Pharmacol.* 140 (2003) 339-346.
- [16] M. Gotthardt, G. Lalyko, J. van Eerd-Vismale, B. Keil, T. Schurrat, M. Hower,
 P. Laverman, T.M. Behr, O.C. Boerman, B. Goke, M. Behe, A new technique for
 in vivo imaging of specific GLP-1 binding sites: first results in small rodents,
Regul. Pept. 137 (2006) 162-167.
- [17] S.E. Kahn, D.B. Carr, M.V. Faulenbach, K.M. Utzschneider, An examination of
 beta-cell function measures and their potential use for estimating beta-cell
 mass, *Diabetes Obes. Metab.* 10 (Suppl. 4) (2008) 63-76.
- [18] M. Schottelius, H.J. Wester, Molecular imaging targeting peptide receptors,
Methods 48 (2009) 161-177.

222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262

Preparation and evaluation of $^{186/188}\text{Re}$ -labeled antibody (A7) for radioimmunotherapy with rhenium(I) tricarbonyl core as a chelate site

Kazuma Ogawa · Hidekazu Kawashima · Seigo Kinuya · Kazuhiro Shiba · Masahisa Onoguchi · Hiroyuki Kimura · Kazuyuki Hashimoto · Akira Odani · Hideo Saji

Received: 16 June 2009 / Accepted: 9 September 2009
© The Japanese Society of Nuclear Medicine 2009

Abstract

Objective Rhenium is one of the most valuable elements for internal radiotherapy because ^{186}Re and ^{188}Re have favorable physical characteristics. However, there are problems when proteins such as antibodies are used as carriers of $^{186/188}\text{Re}$. Labeling methods that use bifunctional chelating agents such as MAG3 require the conjugation of the $^{186/188}\text{Re}$ complex to protein after radiolabeling with the bifunctional chelating agent. These processes are complicated. Therefore, we planned the preparation by a simple method and evaluation of a stable $^{186/188}\text{Re}$ -labeled antibody. For this purpose, we selected $^{186/188}\text{Re(I)}$ tricarbonyl complex as a chelating site. In this study, A7 (an IgG1 murine monoclonal antibody) was used as a model protein. $^{186/188}\text{Re}$ -labeled A7 was prepared by directly reacting a $^{186/188}\text{Re(I)}$ tricarbonyl precursor,

$[\text{}^{186/188}\text{Re}(\text{CO})_3(\text{H}_2\text{O})_3]^+$, with A7. We then compared the biodistribution of $^{186/188}\text{Re}$ -labeled A7 in tumor-bearing mice with ^{125}I -labeled A7.

Methods For labeling A7, $[\text{}^{186/188}\text{Re}(\text{CO})_3(\text{H}_2\text{O})_3]^+$ was prepared according to a published procedure. $^{186/188}\text{Re}$ -labeled A7 ($^{186/188}\text{Re}(\text{CO})_3\text{-A7}$) was prepared by reacting $[\text{}^{186/188}\text{Re}(\text{CO})_3(\text{H}_2\text{O})_3]^+$ with A7 at 43°C for 2 h. Biodistribution experiments were performed by the intravenous administration of $^{186/188}\text{Re}(\text{CO})_3\text{-A7}$ solution into tumor-bearing mice.

Results $^{186}\text{Re}(\text{CO})_3\text{-A7}$ and $^{188}\text{Re}(\text{CO})_3\text{-A7}$ were prepared with radiochemical yields of 23 and 28%, respectively. After purification with a PD-10 column, $^{186/188}\text{Re}(\text{CO})_3\text{-A7}$ showed a radiochemical purity of over 95%. In biodistribution experiments, 13.1 and 13.2% of the injected dose/g of $^{186}\text{Re}(\text{CO})_3\text{-A7}$ and $^{188}\text{Re}(\text{CO})_3\text{-A7}$, respectively, accumulated in the tumor at 24-h postinjection, and the tumor-to-blood ratios were over 2.0 at the same time point. Meanwhile, uptake of $^{125}\text{I}\text{-A7}$ in the tumor was almost the same as that of $^{186/188}\text{Re}(\text{CO})_3\text{-A7}$ at 24-h postinjection. Blood clearances of $^{186/188}\text{Re}(\text{CO})_3\text{-A7}$ were faster than those of $^{125}\text{I}\text{-A7}$.

Conclusion $^{186/188}\text{Re}$ -labeled A7 showed high uptakes in the tumor. However, further modification of the labeling method would be necessary to improve radiochemical yields and their biodistribution.

Keywords Rhenium · Radioimmunotherapy · Antibody · Tricarbonyl

Introduction

Radioimmunotherapy with radiolabeled monoclonal antibodies (mAb) has great potential to be a good treatment

K. Ogawa (✉) · A. Odani
Graduate School of Natural Science and Technology, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan
e-mail: kogawa@p.kanazawa-u.ac.jp

K. Ogawa · K. Shiba
Advanced Science Research Center, Kanazawa University, Kanazawa, Japan

H. Kawashima
Kyoto University Hospital, Kyoto, Japan

S. Kinuya · M. Onoguchi
Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan

H. Kimura · H. Saji
Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan

K. Hashimoto
Japan Atomic Energy Agency, Tokai-mura, Ibaraki, Japan

modality for cancer. In particular, radioimmunotherapy in B-cell non-Hodgkin's lymphoma targeting the CD20 antigen, which is found on the B-cell surface, has clearly demonstrated its efficacy [1, 2]. Consequently, ^{90}Y ibritumomab tiuxetan (Zevalin) and ^{131}I tositumomab (Bexxar), both targeting the CD20 antigen, have been approved by the United States Food and Drug Administration for the treatment of refractory or relapsed low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma [3, 4]. Both radiopharmaceuticals have been shown to produce high response rates, but they also have some shortcomings as radionuclides. ^{131}I emits a high-energy gamma ray, 364 keV, that is not ideal for imaging and exposes patients to unnecessary radiation. Meanwhile, because ^{90}Y is a pure beta emitter, imaging is difficult with ^{90}Y -mAb, and dosimetry should be performed with ^{111}In -mAb before the ^{90}Y -mAb therapy. However, ^{111}In -mAb might not accurately predict the dosimetry of ^{90}Y -mAb because it has been reported that ^{111}In -mAb does not parallel the uptake of ^{86}Y -mAb in bone [5].

Rhenium has two useful radionuclides for radionuclide therapy, ^{186}Re and ^{188}Re . ^{186}Re and ^{188}Re are currently considered to be appropriate candidates for therapeutic applications due to their favorable nuclear properties [6, 7]. Both rhenium radioisotopes decay with the emission of not only beta particles for therapy but also gamma rays, which are suitable for external detection with gamma cameras: ^{186}Re ($t_{1/2} = 3.68$ days, $\beta_{\text{max}}^- = 1.07$ MeV, $\gamma = 137$ keV) and ^{188}Re ($t_{1/2} = 16.98$ h, $\beta_{\text{max}}^- = 2.12$ MeV, $\gamma = 155$ keV). In addition, in the case of ^{188}Re , a further advantage in clinical use is that ^{188}Re is conveniently produced from a transportable, in-house alumina-based $^{188}\text{W}/^{188}\text{Re}$ generator, similar to a $^{99}\text{Mo}/^{99\text{m}}\text{Tc}$ generator [8, 9].

Previous reports have demonstrated the usefulness of $^{186/188}\text{Re}$ radionuclide therapy. However, there are problems when proteins such as antibodies are used as carriers of $^{186/188}\text{Re}$. A direct label method is not ideal because of the instability of labeled mAb, especially in the case of ^{186}Re [10]. The mercaptoacetylglucylglycylglycine (MAG3) ligand forms a stable ^{186}Re -MAG3 complex [11]; the usefulness of ^{186}Re -MAG3-mAb has been demonstrated in preclinical studies [12, 13]. However, the labeling method using bifunctional chelating agents such as the N_3S (MAG3) and N_2S_2 (MAMA) ligand requires conjugation with the $^{186/188}\text{Re}$ complex to mAb after radiolabeling because this radiolabeling procedure requires severe conditions, such as heating and a non-neutral pH [14, 15]. These complicated processes limit the clinical utility of radiolabeled mAb. Thus, we planned the preparation by a simple method and evaluation of a stable $^{186/188}\text{Re}$ -labeled protein. For this purpose, we selected $^{186/188}\text{Re}$ (I) tricarbonyl complex as a chelating site. In this study, A7 (an IgG1 murine mAb) was used as a model protein, and

$^{186/188}\text{Re}$ -labeled A7 was prepared by directly reacting a $^{186/188}\text{Re}$ (I) tricarbonyl precursor, $[\text{}^{186/188}\text{Re}(\text{CO})_3(\text{H}_2\text{O})_3]^+$, with A7. Then, in vitro stability experiments and biodistribution experiments in tumor-bearing mice were performed.

Materials and methods

Materials

^{186}Re and ^{188}W were supplied by the Japan Atomic Energy Agency (Tokai-mura, Japan) as $^{186}\text{ReO}_4^-$ and $^{188}\text{WO}_4^{2-}$ [16]. Alumina acid grade (100–200 mesh) alumina (ICN, Irvine, CA) was used as an adsorbent for the $^{188}\text{W}/^{188}\text{Re}$ generator. Silver cation exchange cartridges (Ag Plus) and anion exchange cartridges (SepPak QMA Light) were purchased from Alltech Associates, Inc. (Deerfield, IL) and Waters Corporation (Milford, MA), respectively. $^{188}\text{ReO}_4^-$ was eluted from a $^{188}\text{W}/^{188}\text{Re}$ generator using saline. The radioactive elution (5 mL) was condensed to a total of 400 μL using the method reported previously [8, 9]. A7, an immunoglobulin G1 murine mAb that recognizes the 45-kDa glycoprotein in human colon cancer, was used. A7 reacts with most colorectal cancers [17]. IsoLink kits for preparing $[\text{}^{186/188}\text{Re}(\text{CO})_3(\text{H}_2\text{O})_3]^+$ were obtained from Mallinckrodt (St Louis, MO). $[\text{}^{125}\text{I}]\text{Sodium iodide}$ was purchased from PerkinElmer (Waltham, MA). Radiolabeling of A7 with ^{125}I was performed by the chloramine-T method [18]. Other reagents were of reagent grade and used as received.

The radiochemical purities of $^{186/188}\text{Re}$ - and ^{125}I -labeled A7 were determined by thin layer chromatography (TLC) and cellulose acetate electrophoresis (CAE) (Separax-SP; Joko Co. Ltd., Tokyo, Japan). TLC analyses were performed with silica plates (Art 5553, Merck, Darmstadt, Germany) with a mixture of 99% methanol and 1% concentrated HCl as a developing solvent. CAE was run at an electrostatic field of 1.0 mA/cm for 20 min in veronal buffer ($I = 0.06$, pH 8.6).

Preparation of $^{186/188}\text{Re}$ -labeled A7 ($^{186/188}\text{Re}(\text{CO})_3\text{-A7}$)

An intermediate of $^{186/188}\text{Re}$ -labeled mAb, $[\text{}^{186/188}\text{Re}(\text{CO})_3(\text{H}_2\text{O})_3]^+$, was prepared using an IsoLink kit according to the method reported previously [19, 20]. Namely, a mixture of 400 μL $^{186/188}\text{ReO}_4^-$ and 6 μL concentrated phosphoric acid was added to an IsoLink kit to which 6 mg $\text{BH}_3\cdot\text{NH}_3$ (Aldrich, Milwaukee, WI) had previously been added. The reaction mixture was heated at 65°C for 15 min with a 20 mL syringe inserted to balance the pressure caused by gas production during the reaction. After the $^{186/188}\text{Re}$ tricarbonyl intermediate solution was adjusted to about pH 7, 200 μL of this solution was added to 80 μL of the A7 mAb

solution (14.7 mg/mL). After 2 h of incubation at 43°C, this reaction mixture was purified with a PD-10 column (GE Healthcare UK Ltd., Buckinghamshire, England) with saline as the eluate.

In vitro stability

To evaluate its stability, $^{188}\text{Re}(\text{CO})_3\text{-A7}$ in saline solution was incubated at 37°C. After incubation for 24 h, a sample was drawn and its radioactivity was analyzed by CAE and TLC. In addition, $^{188}\text{Re}(\text{CO})_3\text{-A7}$ solutions were diluted 10-fold with a 0.1 M solution of histidine or freshly prepared murine plasma, and the solutions were incubated at 37°C. After 1-, 3-, and 24-h incubation, the radioactivity of each sample was analyzed by TLC.

Biodistribution in tumor-bearing mice

Experiments with animals were conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals of Kanazawa University. The animals were housed with free access to food and water at 23°C with a 12-h alternating light/dark schedule. LS180 human colon carcinoma cells were obtained from ATCC (Manassas, VA) and grown in cell culture dishes in Eagle's minimum essential medium with phenol red, 10% heat-inactivated fetal calf serum, 100 µg/mL glutamine, 100 units/mL penicillin, and 100 µg/mL streptomycin. The cells were cultured in a humidified atmosphere of 95% air and 5% carbon dioxide at 37°C. They were then released from the dishes by treatment with 0.05% trypsin/EDTA. Next, to produce tumors, the mice to be inoculated were anesthetized with pentobarbital and approximately 5×10^6 cells were injected subcutaneously into the right shoulder of 4-week-old BALB/c nu/nu female mice (15–19 g). Biodistribution experiments were performed approximately 8 days postinoculation, i.e., the time required for the tumors to reach a palpable size. Groups of four or five mice were administered 100 µL $^{186}\text{Re}(\text{CO})_3\text{-A7}$, $^{188}\text{Re}(\text{CO})_3\text{-A7}$, or $^{125}\text{I-A7}$ (7.4 kBq, A7: 100 µg, respectively) intravenously and killed at 1- and 24-h postinjection. Tissues of interest were removed and weighed, and radioactivity counts were determined with an Auto Well Gamma System (ARC-380; Aloka, Tokyo, Japan) and corrected for background radiation and physical decay during counting.

Results

Preparation of $^{186/188}\text{Re}(\text{CO})_3\text{-A7}$

In TLC analyses, $^{186/188}\text{Re}(\text{CO})_3\text{-A7}$ remained at the original position ($R_f = 0$), while an intermediate,




Fig. 1 Profiles of $^{188}\text{Re}(\text{CO})_3\text{-A7}$ and intact A7 (Ponceau S dye) on cellulose acetate electrophoresis

$^{186/188}\text{Re}(\text{CO})_3(\text{H}_2\text{O})_3]^+$, and the free perrhenate ($^{186/188}\text{ReO}_4^-$) migrated to $R_f = 0.2\text{--}0.4$ and $R_f = 0.7\text{--}0.8$, respectively [20]. In CAE analyses, intact A7 migrated to the 2–2.5 cm anode from the origin, which was determined by Ponceau S dye, and $^{186/188}\text{Re}(\text{CO})_3\text{-A7}$ also migrated to the 2–2.5 cm anode (Fig. 1), while colloidal $^{186/188}\text{Re}$ remained at the origin. The radiolabeling yield of $^{188}\text{Re}(\text{CO})_3(\text{H}_2\text{O})_3]^+$ was 41%. $^{186}\text{Re}(\text{CO})_3\text{-A7}$ and $^{188}\text{Re}(\text{CO})_3\text{-A7}$ were prepared with radiochemical yields of 23 and 28%, respectively. After purification using a PD-10 column, $^{186}\text{Re}(\text{CO})_3\text{-A7}$ and $^{188}\text{Re}(\text{CO})_3\text{-A7}$ showed a radiochemical purity of over 95%.

In vitro stability

After incubation in saline for 24 h, about 93% of the $^{188}\text{Re}(\text{CO})_3\text{-A7}$ remained intact. In murine plasma, over 90% of radioactivity existed in a protein fraction for 24 h, indicating that the $^{188}\text{Re}(\text{CO})_3\text{-A7}$ is not degraded to $^{188}\text{ReO}_4^-$ in plasma. When challenged with an excess of histidine, part of the radioactivity dissociated from $^{188}\text{Re}(\text{CO})_3\text{-A7}$ (Fig. 2).

Biodistribution in tumor-bearing mice

The biodistributions of $^{186}\text{Re}(\text{CO})_3\text{-A7}$, $^{188}\text{Re}(\text{CO})_3\text{-A7}$, and $^{125}\text{I-A7}$ in tumor-bearing mice are listed in Tables 1, 2, and 3. As we expected, both radiorhenium-labeled A7 had almost identical biodistribution. $^{186}\text{Re}(\text{CO})_3\text{-A7}$ and $^{188}\text{Re}(\text{CO})_3\text{-A7}$ showed high uptakes in the tumors, amounting to 13.1 and 13.2% at 24-h postinjection, respectively. Meanwhile, uptake of $^{125}\text{I-A7}$ in the tumor




Fig. 2 Stability of $^{188}\text{Re}-(\text{CO})_3\text{-A7}$ in L-histidine solution

Table 1 Biodistribution of radioactivity after intravenous administration of $^{186}\text{Re}-(\text{CO})_3\text{-A7}$ in mice

Tissue	Time after administration	
	1 h	24 h
Blood	24.8 (1.1)	6.2 (0.3)
Tumor	5.1 (0.7)	13.1 (1.8)
Liver	18.5 (0.4)	9.7 (0.8)
Kidney	13.8 (0.4)	9.0 (1.1)
Intestine	1.5 (0.3)	2.0 (0.2)
Spleen	7.8 (1.0)	4.5 (0.9)
Pancreas	1.1 (0.1)	0.9 (0.0)
Lung	11.8 (2.5)	3.8 (0.5)
Heart	4.4 (0.6)	1.8 (0.1)
Stomach ^a	0.4 (0.0)	0.2 (0.0)
Muscle	0.9 (0.4)	0.8 (0.1)

Data are expressed as % injected dose per gram tissue. Each value represents the mean (SD) of four or five animals

^a Data are expressed as % injected dose

was almost the same as that of $^{186/188}\text{Re}-(\text{CO})_3\text{-A7}$ at 24-h postinjection. Blood clearances of $^{186/188}\text{Re}-(\text{CO})_3\text{-A7}$ were faster than that of $^{125}\text{I-A7}$. $^{186/188}\text{Re}-(\text{CO})_3\text{-A7}$ showed that the tumor/blood ratios were over 2.0 at 24-h postinjection, but the tumor/blood ratio of $^{125}\text{I-A7}$ was approximately 1.0.

Discussion

We hypothesize that the $^{186/188}\text{Re}(\text{CO})_3$ core binds endogenous histidine residue in an antibody when $[\text{}^{186/188}\text{Re}(\text{CO})_3(\text{H}_2\text{O})_3]^+$ is used to label the antibody. In our preliminary experiments, we labeled H-His-OME with $[\text{}^{186}\text{Re}(\text{CO})_3(\text{H}_2\text{O})_3]^+$ at room temperature, 45°C, or 100°C. As a result, the radiochemical yield increased in a

Table 2 Biodistribution of radioactivity after intravenous administration of $^{188}\text{Re}-(\text{CO})_3\text{-A7}$ in mice

Tissue	Time after administration	
	1 h	24 h
Blood	27.6 (1.8)	5.9 (0.8)
Tumor	6.0 (1.7)	13.2 (1.7)
Liver	18.9 (2.8)	9.7 (0.8)
Kidney	14.8 (1.7)	8.9 (0.4)
Intestine	1.8 (0.2)	2.0 (0.3)
Spleen	8.3 (0.8)	4.0 (0.7)
Pancreas	1.5 (0.2)	0.8 (0.0)
Lung	12.6 (2.2)	3.2 (0.4)
Heart	5.6 (0.5)	1.6 (0.3)
Stomach ^a	0.9 (0.2)	0.3 (0.1)
Muscle	0.8 (0.2)	0.5 (0.1)

Data are expressed as % injected dose per gram tissue. Each value represents the mean (SD) of four or five animals

^a Data are expressed as % injected dose

Table 3 Biodistribution of radioactivity after intravenous administration of $^{125}\text{I-A7}$ in mice

Tissue	Time after administration	
	1 h	24 h
Blood	36.7 (4.3)	13.6 (2.1)
Tumor	3.5 (0.7)	13.9 (3.5)
Liver	10.7 (4.5)	3.4 (1.0)
Kidney	8.3 (1.4)	2.9 (0.7)
Intestine	1.6 (0.3)	1.0 (0.3)
Spleen	7.5 (3.2)	2.5 (0.8)
Pancreas	1.3 (0.4)	1.2 (0.2)
Lung	19.8 (2.5)	7.8 (1.2)
Heart	6.9 (1.0)	3.1 (0.5)
Stomach ^a	1.2 (0.2)	1.0 (0.4)
Muscle	0.9 (0.2)	0.8 (0.1)

Data are expressed as % injected dose per gram tissue. Each value represents the mean (SD) of four animals

^a Data are expressed as % injected dose

reaction temperature-dependent manner. In this study, A7 was reacted with $[\text{}^{186/188}\text{Re}(\text{CO})_3(\text{H}_2\text{O})_3]^+$ at 43°C because higher temperatures damage the antibody. Radiochemical yields of $^{186/188}\text{Re}$ -labeled A7 were less than 30%. For clinical use, the radiochemical purity should be over 95% without purification. We suppose that some sequences, such as an oligohistidine sequence, could be inserted into the antibody to improve the radiochemical yield. Tait et al. [21] reported that (His)₆-inserted annexin V had a better radiochemical yield compared with those of (His)₃-inserted annexin V and wild-type annexin V when annexin V was

labeled with [$^{99m}\text{Tc}(\text{CO})_3(\text{H}_2\text{O})_3$] $^+$. Another cause of low radiochemical yields of $^{186/188}\text{Re}$ -labeled A7 could be low yields of [$^{186/188}\text{Re}(\text{CO})_3(\text{H}_2\text{O})_3$] $^+$. In this study, the radiochemical yield of [$^{188}\text{Re}(\text{CO})_3(\text{H}_2\text{O})_3$] $^+$ was only 41%. Recently, higher yields of the preparation of the precursor, [$^{188}\text{Re}(\text{CO})_3(\text{H}_2\text{O})_3$] $^+$, were reported [22, 23]. We assume that using the new method for preparing [$^{186/188}\text{Re}(\text{CO})_3(\text{H}_2\text{O})_3$] $^+$ in future studies would also improve the radiochemical yields of $^{186/188}\text{Re}$ -labeled A7.

The high stability of $^{188}\text{Re}(\text{CO})_3\text{-A7}$ in saline and almost no degradation to $^{188}\text{ReO}_4^-$ in plasma were shown in in vitro experiments. Since accumulation in the stomach is an index of ReO_4^- in biodistribution studies [24], low radioactivity levels in the stomach after injection of $^{186/188}\text{Re}(\text{CO})_3\text{-A7}$ indicate little decomposition to $^{186/188}\text{ReO}_4^-$ in vivo. In a recent study, Chen et al. [23] prepared a ^{188}Re -labeled antibody ($^{188}\text{Re}(\text{I})\text{-trastuzumab}$) by a similar method. $^{188}\text{Re}(\text{I})\text{-trastuzumab}$ showed high stability in vitro and low stomach accumulation in tumor-bearing mice. These studies strongly support the validity of our results.

In other previous studies, it was reported that a radioiodine-labeled antibody, ^{88}Y -isothiocyanatobenzyl-DTPA-antibody, and ^{186}Re -MAG3-antibody showed similar blood clearances [25, 26]. However, in this study, the radioactivity (%dose/g) in blood at 24-h postinjection of $^{186}\text{Re}(\text{CO})_3\text{-A7}$, $^{188}\text{Re}(\text{CO})_3\text{-A7}$, and $^{125}\text{I}\text{-A7}$ was 6.2 ± 0.3 , 5.9 ± 0.8 , and 13.9 ± 3.5 , respectively. That is, $^{186/188}\text{Re}(\text{CO})_3\text{-A7}$ showed faster blood clearance compared with that of $^{125}\text{I}\text{-A7}$ in the biodistribution experiments. These results suggest that $^{186/188}\text{Re}$ detached from A7 in the blood flow. There is a possibility that the binding of the $^{186/188}\text{Re}(\text{CO})_3$ core to A7 is not strong, and so some molecules in the blood might remove the $^{186/188}\text{Re}(\text{CO})_3$ core from $^{186/188}\text{Re}(\text{CO})_3\text{-A7}$. Actually, when $^{188}\text{Re}(\text{CO})_3\text{-A7}$ was challenged with an excess of histidine, part of the radioactivity dissociated from $^{188}\text{Re}(\text{CO})_3\text{-A7}$. In this experiment, the radiochemical purity of $^{188}\text{Re}(\text{CO})_3\text{-A7}$ decreased to around 60% after 3-h incubation. However, after 24-h incubation, the radiochemical purity of $^{188}\text{Re}(\text{CO})_3\text{-A7}$ was almost same as that after 3-h incubation. These results suggest that there are strong and weak bindings of the $^{188}\text{Re}(\text{CO})_3$ core to an A7 antibody in purified $^{188}\text{Re}(\text{CO})_3\text{-A7}$ because the $^{188}\text{Re}(\text{CO})_3$ core does not bind to a specific site in an antibody. Recently, the biodistribution of [$^{188}\text{Re}(\text{CO})_3(\text{H}_2\text{O})_3$] $^+$ was reported [27]. The radioactivity in blood, liver, and kidney at 24-h postinjection of [$^{188}\text{Re}(\text{CO})_3(\text{H}_2\text{O})_3$] $^+$ were 3.13 ± 0.52 , 9.65 ± 1.40 , and 9.62 ± 0.09 , respectively. Taking into account the biodistribution at 24-h postinjection of $^{186/188}\text{Re}(\text{CO})_3\text{-A7}$ in this study, these results are also not inconsistent with our hypothesis.

Faster blood clearance is advantageous for mitigating side effects because myelosuppression is the chief side

effect associated with radioimmunotherapy [28]. However, faster blood clearance compromises the accumulation of radioactivity in tumors. In summary, although diagnostic radiopharmaceuticals should be better because they need a high tumor/blood ratio at an earlier time postinjection, therapeutic radiopharmaceuticals might be unfavorable because high accumulation and long retention in tumors are preferred for a better therapeutic effect. As mentioned above, we suppose that insertion of an oligohistidine sequence could improve the radiochemical yield. In addition, insertion could also be effective from the point of view of improving the in vivo stability and biodistribution of $^{186/188}\text{Re}$ -labeled antibodies.

Conclusion

$^{186/188}\text{Re}$ -labeled A7 showed high uptakes in tumors the same as that of ^{125}I -labeled A7. However, further modifications of the labeling method would be necessary in order to improve radiochemical yields and their biodistribution.

References

- Macklis RM. Radioimmunotherapy as a therapeutic option for non-Hodgkin's lymphoma. *Semin Radiat Oncol.* 2007;17:176–83.
- Dillman RO. Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies. *Clin Exp Med.* 2006;6:1–12.
- Davies AJ. Radioimmunotherapy for B-cell lymphoma: Y^{90} ibritumomab tiuxetan and I^{131} tositumomab. *Oncogene.* 2007;26:3614–28.
- Jacene HA, Filice R, Kasecamp W, Wahl RL. Comparison of ^{90}Y -ibritumomab tiuxetan and ^{131}I -tositumomab in clinical practice. *J Nucl Med.* 2007;48:1767–76.
- Garmestani K, Milenic DE, Plascjak PS, Brechbiel MW. A new and convenient method for purification of ^{86}Y using a Sr(II) selective resin and comparison of biodistribution of ^{86}Y and ^{111}In labeled Herceptin. *Nucl Med Biol.* 2002;29:599–606.
- Ogawa K, Mukai T, Asano D, Kawashima H, Kinuya S, Shiba K, et al. Therapeutic effects of a ^{186}Re -complex-conjugated bisphosphonate for the palliation of metastatic bone pain in an animal model. *J Nucl Med.* 2007;48:122–7.
- Ferro-Flores G, Arteaga de Murphy C. Pharmacokinetics and dosimetry of ^{188}Re -pharmaceuticals. *Adv Drug Deliv Rev.* 2008;60:1389–401.
- Knapp FF Jr, Beets AL, Guhlke S, Zamora PO, Bender H, Palmedo H, et al. Availability of rhenium-188 from the alumina-based tungsten-188/rhenium-188 generator for preparation of rhenium-188-labeled radiopharmaceuticals for cancer treatment. *Anticancer Res.* 1997;17:1783–95.
- Guhlke S, Beets AL, Oetjen K, Mirzadeh S, Biersack HJ, Knapp FF Jr. Simple new method for effective concentration of ^{188}Re solutions from alumina-based ^{188}W - ^{188}Re generator. *J Nucl Med.* 2000;41:1271–8.
- Griffiths GL, Goldenberg DM, Knapp FF Jr, Callahan AP, Chang CH, Hansen HJ. Direct radiolabeling of monoclonal antibodies

- with generator-produced rhenium-188 for radioimmunotherapy: labeling and animal biodistribution studies. *Cancer Res.* 1991;51:4594–602.
11. Ogawa K, Mukai T, Arano Y, Ono M, Hanaoka H, Ishino S, et al. Development of a rhenium-186-labeled MAG3-conjugated bisphosphonate for the palliation of metastatic bone pain based on the concept of bifunctional radiopharmaceuticals. *Bioconjug Chem.* 2005;16:751–7.
 12. Kinuya S, Yokoyama K, Tega H, Hiramatsu T, Konishi S, Yamamoto W, et al. Rhenium-186-mercaptoacetyltriglycine-labeled monoclonal antibody for radioimmunotherapy: in vitro assessment, in vivo kinetics and dosimetry in tumor-bearing nude mice. *Jpn J Cancer Res.* 1998;89:870–8.
 13. Kinuya S, Yokoyama K, Kobayashi K, Motoishi S, Onoma K, Watanabe N, et al. Experimental radioimmunotherapy with ^{186}Re -MAG3-A7 anti-colorectal cancer monoclonal antibody: comparison with ^{131}I -counterpart. *Ann Nucl Med.* 2001;15:199–202.
 14. Visser GW, Gerretsen M, Herscheid JD, Snow GB, van Dongen G. Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol. *J Nucl Med.* 1993;34:1953–63.
 15. Ogawa K, Mukai T, Arano Y, Otaka A, Ueda M, Uehara T, et al. Rhenium-186-monoaminemonoamidedithiol-conjugated bisphosphonate derivatives for bone pain palliation. *Nucl Med Biol.* 2006;33:513–20.
 16. Kobayashi K, Motoishi S, Terunuma K, Rauf AA, Hashimoto K. Production of $^{186,188}\text{Re}$ and recovery of tungsten from spent $^{188}\text{W}/^{188}\text{Re}$ generator. *Radiochemistry.* 2000;42:551–4.
 17. Kotanagi H, Takahashi T, Masuko T, Hashimoto Y, Koyama K. A monoclonal antibody against human colon cancers. *Tohoku J Exp Med.* 1986;148:353–60.
 18. Wilbur DS, Hadley SW, Grant LM, Hyalarides MD. Radioiodinated iodobenzoyl conjugates of a monoclonal antibody Fab fragment. In vivo comparisons with chloramine-T-labeled Fab. *Bioconjug Chem.* 1991;2:111–6.
 19. He J, Liu C, Vanderheyden JL, Liu G, Dou S, Rusckowski M, et al. Radiolabelling morpholinos with ^{188}Re tricarbonyl provides improved in vitro and in vivo stability to re-oxidation. *Nucl Med Commun.* 2004;25:731–6.
 20. Schibli R, Schwarzbach R, Alberto R, Ortner K, Schmalle H, Dumas C, et al. Steps toward high specific activity labeling of biomolecules for therapeutic application: preparation of precursor $[\text{}^{188}\text{Re}(\text{H}_2\text{O})_3(\text{CO})_3]^+$ and synthesis of tailor-made bifunctional ligand systems. *Bioconjug Chem.* 2002;13:750–6.
 21. Tait JF, Smith C, Gibson DF. Development of annexin V mutants suitable for labeling with Tc(i)-carbonyl complex. *Bioconjug Chem.* 2002;13:1119–23.
 22. Park SH, Seifert S, Pietzsch HJ. Novel and efficient preparation of precursor $[\text{}^{188}\text{Re}(\text{OH})_2(\text{CO})_3]^+$ for the labeling of biomolecules. *Bioconjug Chem.* 2006;17:223–5.
 23. Chen KT, Lee TW, Lo JM. In vivo examination of $^{188}\text{Re}(\text{I})$ -tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer. *Nucl Med Biol.* 2009;36:355–61.
 24. Lin WY, Hsieh JF, Tsai SC, Yen TC, Wang SJ, Knapp FF Jr. A comprehensive study on the blockage of thyroid and gastric uptakes of ^{188}Re -perrhenate in endovascular irradiation using liquid-filled balloon to prevent restenosis. *Nucl Med Biol.* 2000;27:83–7.
 25. Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, et al. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with ^{131}I , ^{90}Y , ^{177}Lu , or ^{186}Re . *J Nucl Med.* 2004;45:327–37.
 26. Koppe MJ, Bleichrodt RP, Soede AC, Verhofstad AA, Goldenberg DM, Oyen WJ, et al. Biodistribution and therapeutic efficacy of $^{125/131}\text{I}$ -, ^{186}Re -, $^{88/90}\text{Y}$ -, or ^{177}Lu -labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. *J Nucl Med.* 2004;45:1224–32.
 27. Xia JY, Wang YX, Li GC, Yu JF, Yin DZ. Synthesis of pyridyl derivatives for the future functionalization of biomolecules labeled with the fac- $[\text{Re}-188(\text{CO})_3(\text{H}_2\text{O})_3]^+$ precursor. *J Radioanal Nucl Chem.* 2009;279:245–52.
 28. Oriuchi N, Higuchi T, Hanaoka H, Iida Y, Endo K. Current status of cancer therapy with radiolabeled monoclonal antibody. *Ann Nucl Med.* 2005;19:355–65.